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Metastasis is the cause of death in the majority (~90%) of malignant cancers. The oral 
potassium-sparing diuretic amiloride and its 5-substituted derivative 5-N,N-
(hexamethylene)amiloride (HMA) reportedly show robust anti-tumor/metastasis effects in 
multiple in vitro and animal models. These effects are likely due, at least in part, to inhibition of 
the urokinase plasminogen activator (uPA), a key protease determinant of cell invasiveness and 
metastasis. This study reports the discovery of 6-substituted HMA analogs that show nanomolar 
potency against uPA, high selectivity over related trypsin-like serine proteases and minimal 
inhibitory effects against epithelial sodium channels (ENaC), the diuretic and anti-kaliuretic 
target of amiloride. Reductions in lung metastases were demonstrated for two analogs in a late-
stage experimental mouse metastasis model and one analog completely inhibited formation of 
liver metastases in an orthotopic xenograft mouse model of pancreatic cancer. The results 







The urokinase plasminogen activator (uPA) is a trypsin-like serine protease (TLSP) that has 
been implicated in the invasive spread and metastatic dissemination of transformed cells in 
several aggressive cancers, including triple-negative breast, pancreatic, gastric, colorectal and 
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prostate cancers.1-5 Clinically, uPA expression provides the highest level of evidence (Level 1)6 
for predicting poor patient prognosis in breast cancer and it is one of the strongest predictors of 
progression-free survival and overall survival.7-9 
uPA binds to cell surfaces via a specific interaction with its cognate receptor urokinase 
plasminogen activator receptor (uPAR), which is expressed on cancer cells and the supporting 
stroma, often at the invasive front of tumors.10-12 uPAR-bound uPA activates co-localised 
plasminogen to yield the broad spectrum TLSP plasmin,13 a key mediator of directed pericellular 
proteolysis that activates multiple downstream proteases (e.g. matrix metalloproteinases and 
cathepsins), ultimately leading to degradation of the extracellular matrix and basement 
membrane components that confine primary tumors.3, 14-15 The uPA-initiated proteolytic cascade 
is thus a key determinant of local invasion and metastatic spread via the lymphatic and 
circulatory systems.16-17  
uPA attracted much interest in the 1990’s and early 2000’s as an anticancer target in academic 
and industry labs (reviewed in Ngo et al.18 and Tyndall et al.19). For example, efforts from 
Abbott Laboratories led to highly potent naphthamidine-based inhibitors; e.g. 1.23-26 X-ray co-
crystal structures of these and other inhibitors uncovered a novel subsite, termed S1β, adjacent to 
the S1 binding pocket in uPA. Targeting of this site afforded potency gains in a variety of aryl 
amidine-based inhibitors.23 The poor drug properties of arylamidines ultimately proved to be a 
major stumbling block, however, and compounds were not advanced to the clinic.27 Astex 
Therapeutics were able to repurpose the oral anti-arrhythmic drug mexiletine into a potent, orally 
active non amidine-containing uPA inhibitor 228 but no clinical studies have been reported to 
date. 
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3a and its oral hydroxyamidine prodrug 3b (Heidelberg Pharma AG; formerly WILEX AG) 
are, to the best of our knowledge, the only uPA inhibitors to have undergone clinical evaluation 
in cancer.29 Phase II studies of oral 3b in combination with gemcitabine showed a 17% increase 
in 1-year survival in patients with locally advanced, non-resectable pancreatic cancers compared 
to patients treated with gemcitabine alone.30 In a separate Phase II study, patients with HER2-
negative metastatic breast cancers who had received adjuvant chemotherapy following primary 
diagnosis and were subsequently treated with 3b in combination with capecitabine showed an 
increase in median progression-free survival (8.3 months) compared to patients receiving 
capecitabine alone (4.3 months).31  
Amiloride 4 is an oral potassium-sparing diuretic that has been used for over four decades in 
the treatment of hypokalemia, hypertension and cirrhosis.32-33 The diuretic and antikaliuretic 
properties of amiloride arise through inhibition of renal epithelial sodium channels (ENaCs).34-35 
Several groups have reported that the compound also shows anticancer side-activities in multiple 
in vitro and rodent models (reviewed in Matthews et al.).16 In one study, high doses of amiloride 
(200 mg/kg in drinking water ad libitum) caused complete remission in a prostate xenograft 
mouse model.36 It has been suggested that the anticancer effects of amiloride observed at the 
high doses used in this and other animal studies likely arise, at least in part, from inhibition of 
uPA proteolytic activity (IC50 = 7 µM).
37 Amiloride is unsuitable for use clinically as an 
anticancer drug, however, due to its low maximum daily dose ceiling (20 mg/day), where 
overdose risks hyperkalemia and associated cardiac events.38 Nevertheless, the demonstrable in 
vivo anticancer side-activities of amiloride, combined with excellent drug-like properties 
(inferred from decades of oral clinical use) and low micromolar potency against uPA, suggest it 
as an attractive starting scaffold for repurposing using the Selective Optimization of Side-
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Activity (SOSA) approach39 into a high potency uPA inhibitor for treating uPA-driven cancers.16 
Moreover, the reduced basicity of the acyl guanidine group relative to aryl amidines potentially 
offers a solution to the poor drug properties of earlier inhibitors.27 We propose that effective 
dosing of an analog suitably optimized for high uPA potency that lacks the diuretic and anti-
kaliuretic effects of amiloride may safely and effectively recapitulate in humans the anticancer 
activities observed with high doses of amiloride in animals. 
 
 
Figure 1. Structures of reported uPA inhibitors. 
 
Our preliminary structure-activity exploration of amiloride analogs as uPA inhibitors focused 
on the effects of varying substituents at the 5-NH2 group.
40 Relatively flat SAR trends were 
observed, with multiple analogs carrying diverse 5-substituents returning IC50 values in the range 
1-50 µM. Large increases in potency relative to amiloride were not realized, with the most active 
compound (5-N,N’-dimethylethylenediamine amiloride) showing only a ~2-fold increase (IC50 = 
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3 µM). A key finding, however, was that 5-N,N-(hexamethylene)amiloride 5 (HMA, Figure 1) 
retained potency against uPA (IC50 = 6 µM). 
HMA has a long history of use as a pharmacological tool41 and, like amiloride, reportedly 
shows in vitro and in vivo anti-cancer activities.42-47 For example, HMA has been shown to delay 
primary tumor growth and increase thermosensitivity of SCK mammary carcinoma cells in a 
mouse allograft model,42, 48 and it was recently shown to suppress sorafenib-resistant engraftment 
of FLT3-ITD+ acute myeloid leukemia primary cells in mice, with total suppression observed in 
combination with sorafenib.45 Importantly, alkyl substitution of the 5-NH2 group of amiloride (as 
in HMA) appears to reduce inhibitory effects against ENaCs.48-49 Based on this, HMA 5 was 
selected as the starting point for SOSA optimization. 
There have been many structure-activity studies exploring the effects of substitution at various 
positions around the pyrazine core of amiloride48 but there is a surprising lack of reports on 
analogs carrying variations at the 6-position of amiloride, HMA or any other 5-substituted 
amilorides.50 This study reports the synthesis, uPA structure-activity relationships and in vivo 




RESULTS AND DISCUSSION 
Chemistry. The reported X-ray co-crystal structure of amiloride bound to uPA51 indicated 
that the 6-Cl group projects towards the S1β subsite, suggesting that other groups attached here 
might better occupy the site and increase potency. A diverse series of 6-(hetero)aryl substituted 
HMA analogs was produced from the common 5-N,N-(hexamethylene)amiloride methyl ester 
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intermediate 7 (Scheme 1). Ester 7 was obtained via nucleophilic aromatic substitution of the 
commercially available 3-amino-5,6-dichloropyrazine-2-methyl ester 6 with 
hexamethyleneimine. The reported method for preparing 7,40 which involves heating 6 with 
hexamethyleneamine in DMF at 100 °C for 1 hour, requires multiple column chromatography 
steps to obtain pure  7 (65% yield). We found that when the reaction was instead performed at 
reflux in 2-propanol in the presence of N,N-diisopropylethylamine (DIPEA), an excellent yield 
of 7 (86%) was obtained after only 2 hours. The improved procedure could be performed on 
multi-gram scale in an open flask with the pure 7 crystallizing from the reaction mixture and 
isolated by simple filtration. 
Direct attachment of (hetero)aryl substituents to the 6-position of 7 was achieved using 
standard Suzuki-Miyaura cross-coupling conditions with commercial aryl boronic acids (or 
pinacol boronates), Pd(PPh3)4 and K2CO3 in toluene/MeOH (4:1) at reflux. A total of twenty 
three 6-(hetero)aryl methyl esters 9a-32a were produced in yields ranging from 34-93%. The 
methyl esters were converted to their respective acylguanidines 9-32 in 2-92% by treatment with 
guanidine. Low guanidinylation yields were initially obtained using the reported method40 
leading us to search for an improved procedure. Treating the methyl esters in DMF with a 2 M 
stock solution of guanidine in MeOH was found to give much higher yields, with most reactions 
proceeding to completion at room temperature and and no major side products forming. The 
revised procedure was simple to carry out, allowed multiple guanidinylation reactions to be 
performed in parallel and the 2 M guanidine solution could be stored under N2 in a refrigerator 
for up to 2 weeks.52 
 





aReagents and conditions: (a) (CH2)6NH, DIPEA, 
iPrOH, reflux, 2 h, 86%; (b) R-B(OH)2 or R-
B(pin), Pd(PPh3)4, K2CO3, toluene/MeOH (4:1), reflux, 0.5-18 h; (c) guanidine (2 M in MeOH), 
DMF, rt, 18 h. 
 
6-(2-(Alkylamino)pyrimidin-5-yl) HMA analogs 33-35 (Scheme 2) were obtained from 6-(2-
chloropyrimidin-5-yl) methyl ester intermediate 8.  Compound 8 was synthesized in 64% yield 
by Suzuki-Miyaura coupling of 7 with (2-chloropyrimidin-5-yl)boronic acid. Nucleophilic 
aromatic substitution of the 2-chloro group with the requisite amines yielded esters 33a-35a in 
83-87% yields, which were converted to acyl guanidines 33-35 in 85-89% yields using the new 
guanidinylation procedure. 
 




aReagents and conditions: (a) (2-Chloropyrimidin-5-yl)boronic acid, Pd(PPh3)4, K2CO3, 
toluene/MeOH (4:1), reflux, 18 h, 64%; (b) (i) R-NH2, DIPEA, DMF, rt, 2 d or (ii) R-NH2, 
DIPEA, i-PrOH, reflux, 4 h, 83-87%; (c) guanidine (2 M in MeOH), DMF, rt, 18 h, 85-89%. 
 
Previous reports describing napthamidine-based inhibitors23-24 identified that the 2-
aminopyrimidine group shows favorable binding in the uPA S1β pocket. Based on this, 2-
aminopyrimidinyl derivative 41 was synthesized using the route outlined in Scheme 3. The 3-
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NH2 group of methyl ester 7 was di-Boc protected using Boc-anhydride to give 36 in 85% yield. 
Halogen exchange from the 6-chloro group to 6-bromo in preparation for Buchwald-Hartwig 
amination was carried out over two steps. Hydrodechlorination using 1 atmosphere of hydrogen 
in the presence of Pd/C and MgO was successful, although it was accompanied by loss of one 
Boc-group giving mono-Boc derivative 37 in 92% yield. Introduction of the 6-bromo substituent 
using N-bromosuccinimide (NBS) gave 38 (60% yield) and Buchwald-Hartwig amination of 38 
with 2-aminopyrimidine using Pd2(dba)3/Xantphos afforded the 6-substituted pyrazine methyl 
ester 39 in 30% yield. Removal of the remaining Boc-group with trifluoroacetic acid (98% yield) 
followed by guanidinylation delivered 41 (35% yield). 
 
Scheme 3. Synthesis of 2-aminopyrimidinyl derivative 41a 
 
aReagents and conditions: (a) (Boc)2O, CH2Cl2, DIPEA, N,N-dimethylaminopyridine (DMAP), 
rt, 16 h, 85%; (b) Pd/C, H2 (1 atm), MgO, MeOH, rt, 48 h, 92%; (c) N-bromosuccinimide, 
CH2Cl2, rt, 5 h, 60%; (d) 2-aminopyrimidine, Pd2(dba)3/Xantphos, 1,4-dioxane, Cs2CO3, 100 °C, 
18 h, 30%; (e) TFA, CH2Cl2, rt, 16 h, 98%; (f) guanidine (2M in MeOH), DMF, rt, 35%. 
 
Inhibition of uPA and structure-activity relationships. Inhibition of catalytically active, low 
molecular weight human uPA by 9-35 and 41 was determined using a fluorometric enzyme 
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activity assay.53 Concentration-response curves for representative analogs 18 and 27 are provided 
in Figure 2 and  calculated Ki values are presented in Table 1.  
 
 
Figure 2. Inhibition of low molecular weight human uPA by 18 (black) and 27 (red). Data points 
represent the mean ± SEM (n = 3) from a single representative experiment. 
 
 
Table 1. Inhibition of uPA by 6-substituted HMA analogs. For compounds where n >1, values 
represent the mean ± SEM from identical repeat assays conducted on different days. Ki were 




Amiloride 4 and HMA 5 returned Ki values of 2,433 nM and 1,356 nM, respectively, under the 
assay conditions. Replacing the 6-Cl group of HMA with a phenyl substituent 9 led to ~3.7-fold 
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decrease in potency. Substitution of the phenyl ring at the para-position (10 and 11) did not 
improve potency, while conversion to the 3,4-methylenedioxy derivative 12 provided a slight 
increase relative to HMA (Ki= 934 nM). Appending an isoquinolyl group 13 reduced activity 
nearly 3-fold relative to HMA. N-methylpyrazole derivative 14 showed a ~ 2.7-fold increase(Ki= 
508 nM). Extension of the N-methyl group of 14 to N-ethylmorpholino 15 had only a minor 
effect (Ki = 658 nM). Surprisingly, while 2-indolyl 16 and 2-benzothiophenyl substituents 17 
showed reduced activity, the single atom change to 2-benzofuranyl derivative 18 afforded a 
significant boost in potency (Ki = 183 nM), which increased 2-fold upon addition of a fluorine 
atom at the benzofuran 4-position (19, Ki = 88 nM). The preference for oxygen in the heteroaryl 
ring was also seen with the 2- and 3-furanyl derivatives 22 and 23, respectively, which both 
showed nM potency whereas 2- and 3-thiophene derivatives 20 and 21 were micromolar 
inhibitors. 
2-Fluoropyridine substitution (24 Ki = 1,778 nM) afforded similar activity to HMA 5, while 
addition of a 5-pyrimidinyl group 25 (Ki = 108 nM) gave a ~12.6-fold increase. Addition of a 
methoxy group to the pyrimidine 2-position yielded the first sub-100 nM inhibitor 26 (Ki = 53 
nM), and adding a second methoxy group to the pyrimidine 4-position 27 (Ki = 42 nM) gave a 
further increase. The favorable binding of the pyrimidine group was evident from the significant 
losses in potency observed with dimethoxypyridine 28 and dimethoxyphenyl derivatives 29 and 
30. Loss of potency with the dimethoxypyridazine 31 was less dramatic (Ki = 315 nM). An 
additional 2-fold gain in potency was achieved upon addition of an amine to the pyrimidine 2-
position, yielding the most potent inhibitor in the study (32 Ki = 21 nM). Further gains in 
potency were not obtained through N-alkyl substitution, with N-methyl 33, N-isopropyl 34 and 
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N-hydroxyethyl 35 derivatives showing activity similar to 26. The 2-aminopyrimidine derivative 
41 obtained using Buchwald-Hartwig chemistry showed lower potency (Ki = 228 nM). 
 
X-ray crystallography. An X-ray co-crystal structure was obtained for HMA 5 bound to the 
catalytic domain of human uPA (Figure 3). The binding orientation and interactions observed in 
the HMA:uPA structure mirrored those previously observed with amiloride 4.51 The key salt 
bridge interaction was present between the acylguanidine of HMA and the Asp189 side chain 
carboxylate located at the base of the S1 binding pocket. H-bonds were present between the 
backbone carbonyl of Gly219 and the terminal NH and amide NH groups of the acyl guanidine. 
The second terminal guanidine-NH formed an H-bond to the side chain hydroxyl of Ser190 and 
the exocyclic NH2 group at C3 formed an H-bond to the side chain hydroxyl of Ser195. A 
bridging H-bond network was observed between a surface-bound water molecule, the acyl 
guanidine carbonyl oxygen, Ser190 side chain hydroxyl and a guanidine NH group. A sulfate ion 
from the crystallization buffer was observed in the oxyanion hole of both structures. 
 
Figure 3. X-ray co-crystal structures of (a) amiloride 451 (PDB ID: 1F5L) and (b) HMA 5 (PDB 
ID: 5ZA7, 1.7 Å resolution) bound to uPA. Blue wire basket = 2mFo-DFC map contoured at 1.5 
σ. 
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X-ray co-crystal structures were similarly obtained for benzofuran (18, 19), furan (22, 23), 
pyrimidine 25, 2-methoxypyrimidine 26, 2,4-dimethoxypyrimidine 27 and N-methylpyrazole 14 
analogs (Figures 4 and 5. X-ray refinement statistics are provided in Supporting Information, 
Table S1). H-bonding networks reminiscent of those seen in the HMA:uPA structure were 
observed in all complexes. The 7-membered hexamethylene ring appeared to sample multiple 
conformations, as evidenced by low electron density in all structures. Replacement of the 6-Cl 
group with (hetero)aryl substituents did not significantly alter the binding positions or orientation 
of the pyrazine core or acylguanidines relative to HMA 5. The 6-substituent occupied S1β in all 
cases and sulfate ion occupied the oxyanion hole in some complexes. 
The structure obtained with 2-furanyl analog 22 (Figure 4a) revealed that the ~8.7-fold 
increase in potency relative to HMA 5 may arise from new H-bonds formed between the furanyl 
O, a bridging water molecule and the amide NH of Gly219. Favorable van der Waals contacts 
between the furan ring and Gly219, the Cys191-Cys220 disulfide, Ser146 backbone carbonyl and 
the side chain Cβ and Cγ of Gln192 were also apparent. Changing to the 3-furanyl substituent 23 
had little effect on uPA activity despite the furanyl oxygen no longer making the water-bridged 
H-bond interaction with Gly219 (Figure 4b). Flexibility of the Arg217 side chain was noted in 
this structure, where it had shifted towards S1β to participate in the Gly219-bridging water H-
bond network. Relative to 22, the plane of the furan ring in 23 was tilted 11˚, a pose that 
promoted van der Waals interactions with Cys220. Interactions with S1β residues Cys191-
Cys220, Ser146 and the Gln192 side chain were preserved and there appeared to be a dipolar 
interaction between the side chain carbonyl of Gln192 and the polarized furan 2-CH group. 
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Ring fusion to give benzofuran 18 led to a slight decrease in potency (Ki = 183 nM) relative to 
22 despite this group extending further into S1β and almost completely occupying the subsite 
(Figure 4c). The plane of the benzofuran ring was essentially perpendicular to the pyrazine core 
but the ring oxygen had flipped 180° relative to the furanyl oxygen of 22. This orientation 
allowed the benzofuran 7-CH group to fill a small, hydrophobic dimple formed by Lys143, 
Gln192 and Ser146. Additional hydrophobic contacts were seen between the benzofuran 3- and 
4-position CH groups and Gly219. Similar to what was observed in the HMA 5 and 22 
structures, the side chain of Arg217 adopted a conformation well away from S1β. The structure 
with 19 suggested that the 2-fold increase in potency obtained after fluorine substitution at the 
benzofuran 4-position (19 Ki = 88 nM) arose from favorable interactions between the 4-fluoro 
group and the side chain guanidine of Arg217 (possibly an H-bond), which had shifted back 
towards S1β in this complex. The interaction with Arg217 also appeared to cause a slight 
twisting about the benzofuran-pyrazine axis away from perpendicular, with the 78° dihedral 
angle in 18 reducing to 68° in 19. 
 16
 
Figure 4. X-ray co-crystal structures of: (a) 22 (PDB ID: 5ZAE, 1.7Å), (b) 23 (PDB ID: 5ZAF, 
1.7Å), (c) 18 (PDB ID: 5ZA9, 1.6Å) and (d) 19 (PDB ID: 5ZC5, 1.9Å) bound to uPA. Blue wire 
baskets represent 2mFo-DFC maps contoured at 1.5 σ. 
 
The 5-pyrimidine substituent of 25 was found to partially occupy S1β (Figure 5a), making 
van der Waals interactions with the Cys191-Cys220 disulfide, Ser146 and Gln192 residues. A 
dipole interaction between the polarized 4-CH group of the pyrimidine and the Gln192 side chain 
carbonyl appeared to be present, along with an H-bond between the amide NH of Gly219 and the 
lone pair of electrons on a pyrimidine nitrogen. The polarized 6-CH on the pyrimidine appeared 
to interact with the Gly219 carbonyl group. 
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Addition of a methoxy group to the pyrimidine 2-position 26 led to a ~ 2-fold increase in 
potency, but it did not appear to make any specific interactions with the protein, instead orienting 
towards bulk solvent (Figure 5b). The sidechain of Arg217 had flipped back towards S1β driven 
by a polar interaction with the pyrimidine nitrogen (possibly an H-bond).  
Introduction of a second methoxy substituent onto the pyrimidine ring 27 resulted in a small 
increase in potency relative to 26. The pyrimidine and pyrazine rings were almost perpendicular 
(dihedral angle 80°), allowing for increased occupancy of S1β and projection of a methoxy 
group towards the small hydrophobic dimple formed by Lys143, Gln192 and Ser146 (Figure 5c). 
The second methoxy substituent was projected towards bulk solvent. In contrast to 25 and 26, the 
Arg217 side chain was positioned well away from S1β, apparently to avoid a steric clash with 
the pyrimidine 2-OCH3 group of 27. 
The N-methylpyrazole substituent of 14 adopted a coplanar arrangement with the pyrazine 
reducing its penetration into S1β (Figure 5d). Interactions were observed between the pyrazole 3-
CH and 5-CH groups and the backbone of Gly219 and the side chain of Gln192, respectively. 
The surface water molecule bound to Gly219 in the furanyl structures 22 and 23 was observed 




Figure 5. X-ray co-crystal structures of: (a) 25 (PDB ID: 5ZAG, 2.0 Å), (b) 26 (PDB ID: 5ZAH, 
3.0 Å), (c) 27 (PDB ID: 5ZAJ, 1.7 Å) and (d) 14 (PDB ID: 5ZA8, 1.9 Å) bound to uPA. Blue 
wire baskets represent 2mFo-DFC maps contoured at 1.5 σ. 
 
 
Inhibition of trypsin-like serine proteases. HMA 5 and 6-substituted analogs 18, 19 and 26 
were screened against a panel of trypsin-like serine proteases (TLSPs) using chromogenic assays 
(Table 2). Comparable uPA inhibition was observed with the four compounds under 
chromogenic (Table 1) and fluorometric (Table 2) assay conditions. In agreement with earlier 
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reports showing that occupancy of uPA’s S1β subsite confers high selectivity over other 
TLSPs,20, 23, 55 each of the compounds showed 20-100+ fold selectivity for uPA. 
 
Table 2. uPA selectivity versus related trypsin-like serine proteases of HMA 5 and 6-substituted 
analogs 18, 19 and 26. Values were obtained using chromogenic enzyme inhibition assays.40 N/D 
= not determined.  
IC50 ( M)
Compound Human plasma Factor Xa Factor XIa ActivatedR uPA tPA Plasmin Thrombin Trypsin
>50 >50 >50 >505 2.4 >10 >10 >10 >10
11.3 >50 31.0 >50
16.7 >50 23.3 >50
0.53 >10 >10 >10
0.43 >20 >20 >20
>10
N/D



















To further probe uPA selectivity, super-family wide screening against 85 serine hydrolases 
was performed in-situ using the recently described EnPlex activity-based protein profiling 
(ABPP) assay56. In this approach, individual serine hydrolases are conjugated to differently 
colored Luminex beads and the ability of inhibitory compounds to outcompete a biotinylated 
serine-reactive/SAPE probe at the active site of each enzyme provides a rapid and semi-
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quantitative readout of enzyme inhibition. Results from the Enplex screen with amiloride 4, 




Figure 6. EnPlex56 screening of amiloride 4, HMA 5 and analogs 18, 25 and 26 for inhibition of 85 serine hydrolases. 
Grey boxes indicate wells in which no fluorescence was observed. The singular readouts suggesting activity of 4 and 26 
against LIPE are artifacts. Black arrows indicate decreasing compound concentration from 33.3 µM to 10 nM. 
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Amiloride showed slight activity against only a few serine hydrolases (C1R,C1S, DDHD1, 
Factor VIIa and LACTB), consistent with its reported high  selectivity for uPA.37 HMA 5 showed 
activity against the highly homologous S28 protease family members dipeptidyl peptidase 2 
(DPP7) and prolylcarboxypeptidase (PRCP).57 Surprisingly, inhibitory activity against uPA was 
not observed for HMA under these assay conditions. 2-Benzofuranyl analog 18 showed the least 
selectivity among the tested compounds, inhibiting plasma kallikrein (KLKb1) and trypsin. 5-
Pyrimidinyl analog 25 showed remarkable selectivity for uPA, with slight inhibition of trypsin 
being the only off-target TLSP activity observed. 2-Methoxy pyrimidinyl analog 26 showed 
slight activity against C1S, plasma kallikrein, plasmin, prolylcarboxy peptidase, trypsin and 
transmembrane protease serine 11D (TMPRSS11d).  
 
Human cell cytotoxicity. HMA 5 and representative analogs 18, 19, 25 and 26 were tested 
for cytotoxicity against four human cell lines (Table 3). HMA 5 showed toxicity in the low 
micromolar range against all cell lines, with HEK-293 embryonic kidney and HT-1080 
fibrosarcoma cells being most sensitive. In general, the cell lines were more sensitive to 18, 
suggesting the benzofuran group may contribute to cytotoxic effects. MDA-MB-231 cells were 
~3-fold more sensitive to the 4-fluorinated benzofuran 19 but the compound was less toxic than 
18 towards the other three cell types. Cytotoxicity was not a general feature of 6-substituted 
HMA analogs since pyrimidine analogs 25 and 26 showed much lower activity against all cells. 
The lower logD7.4 of the pyrimidines (i.e. 2.8 and 3.4, respectively) relative to benzofuran 18 (i.e. 
logD7.4 5.1) and HMA (logD7.4 3.8) suggests lipophilicity may be a contributor to cytotoxicity. 
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Table 3. Effect of HMA and selected analogs on human cell viability. 
 
 
Off-target activity against GPCRs. Amiloride and related analogs are known to bind to G-
protein coupled receptors (GPCRs).58-59 For example, amiloride is a known antagonist of the 
adenosine 2A receptor (A2A).
60-62 Recent work describing the effects of substitution at the 
amiloride 5-position on A2A antagonism identified analogs with increased potency, including 
HMA 5.63 In the current study, a representative selection of 6-substituted HMA analogs were 
evaluated alongside HMA 5 for A2A antagonism using a radiolabeled ligand displacement assay 
(Figure 7). In all cases, the presence of the 6-substituent diminished antagonist effects relative to 
HMA, with the majority of compounds showing poor A2A binding. 
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Figure 7. Single concentration screening (10 µM) of HMA 5 and 6-substituted HMA analogs as 
antagonists of the human adenosine A2A receptor (hA2AAR-WT). Radioligand [
3H]ZM241385 
was present at 2.5 nM. Total binding (TB, 100%) of [3H]ZM241385 was determined in the 
absence of inhibitors. Non-specific binding (NSB, 0%) was determined in the presence of 100 
µM A2A agonist 5’-(N-ethylcarboxamido)adenosine (NECA). Data represent the mean ± SEM 
from at least three independent experiments conducted in duplicate. Methods were as described 
in reference 63. 
 
Development of active site-directed uPA inhibitors has been complicated by the observation 
that compounds optimized for high affinity against human uPA often show reduced potency 
against the homologous mouse enzyme.64 This species selectivity can confound interpretation of 
data from mouse models as the decreased affinity for mouse uPA may lead to an underestimation 
of compound efficacy. To explore this issue in the 6-substituted HMA class, we measured the 
activities of 4, 5, 18 and 26 against mouse uPA (Table 4). 
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Table 4. Activity of compounds 4, 5, 18 and 26 against human and mouse uPA. aExperimental 




Amiloride 4 was essentially equipotent against mouse and human uPA. Addition of the 5-
hexamethylene ring in 5 decreased affinity for mouse uPA by almost 7-fold, while compounds 
18 and 26 showed larger (10- to 30-fold) reductions. These findings align with reported trends 
for compounds bearing substituents that target uPA’s S1β subsite.64 The lower potency against 




Diuretic and anti-kaliuretic effects. The potassium-sparing activity of amiloride arises from 
inhibition of epithelial sodium channels (ENaCs) in the kidneys, leading to reduced urinary 
excretion of K+.34 In cases of overdose, the potassium-sparing effects can lead to hyperkalemia 
and cardiac arrhythmias.65 As such, removal of ENaC activity is essential for development of a 
6-substituted HMA analog suitable for use in cancer. Early work from the Cragoe group at 
Merck established that alkyl substitution of the 5-NH2 group of amiloride reduces ENaC 
activity,49 and showed that HMA produces >80-fold lower inhibition than amiloride in a 
deoxycorticosterone acetate (DOCA) induced K+ excretion model in adrenalectomized rats.49 6-
Substituted HMA analogs were thus expected to show similarly low activity against ENaCs. To 
confirm this, a representative selection of analogs was tested against recombinant HEK-293 cells 
that overexpress the α, β and γ subunits of human ENaCs (Figure 8). In line with expectations, 
amiloride 4 produced a strong effect (68% inhibition of ENaC at 10 µM), whereas HMA 5 
showed greatly reduced activity and 6-substituted analogs 11, 18, 25 and 26 showed similar or 
lower inhibition than HMA.  
 
Figure 8. Inhibition of ENaC activity by amiloride 4, HMA 5 and 6-substituted analogs 11, 18, 
25 and 26 in transfected HEK-293 cells. All compounds were present at 10 µM. Data represent 
the mean ± SD (n = 4).  
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Amiloride 4, HMA 5 and analogs 18 and 26 were next tested in a rat model of diuresis to 
confirm that loss of ENaC inhibitory potency corresponded to an absence of diuretic and anti-
kaliuretic effects in vivo (Figure 9). With the exception of vehicle controls, all animals were 
dosed with 25 mg/kg acetazolamide to induce diuresis66 prior to receiving 1.5 mg/kg of 
amiloride 4, HMA 5, 18 or 26. Urine was collected over a 6 h period following dosing. 
Consistent with previous reports, amiloride 4 showed potent diuretic and anti-kaliuretic effects, 
increasing urine volume and sodium excretion by 34% and 159% respectively, while decreasing 
potassium excretion by 92% relative to acetazolamide-treated controls (Na+/K+ excretion ratio = 
63, p <0.0001 for all measurements).66 Compound 18 did not significantly decrease K+ 
excretion, while HMA 5 and 2-methoxypyrimidine analog 26 showed a very slight potassium-
sparing effect (24% reduction, p <0.001). HMA 5, 18 and 26 did not alter Na+ excretion or urine 
volume and the Na+/K+ excretion ratios for the three compounds were no different to 
acetazolamide treated controls (range = 2.44-2.68).  
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Figure 9. Effects of amiloride 4, HMA 5 and 6-substituted analogs 18 and 26 on urine flow and 
excretion of Na+ and K+ in Sprague Dawley rats. Rats were dosed with 25 mg/kg acetazolamide 
prior to administering 1.5 mg/kg of test compound. Data represent the mean ± SEM (n = 8). ** = 
p <0.001, **** = p <0.0001 relative to acetazolamide control.  
 
Experimental lung metastasis model. Two analogs were advanced to anti-cancer pilot studies 
to establish efficacy in-vivo. Compounds 18 and 26 were selected as representative examples 
showing different potency and polarity (18 logD7.4 = 5.1, 26 logD7.4 = 3.4). In the first study, 
amiloride 4 and 6-substituted HMA analogs 18 and 26 were examined for anti-metastasis effects 
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in an experimental mouse model of late-stage lung metastasis. Luciferase-tagged HT-1080 
human fibrosarcoma cells were used in the model after confirming cell surface expression of 
uPA/uPAR (Supporting Information Figure S1). Assays of lung homogenates following organ 
harvest at endpoint were used to quantitate lung tumor burden and response to treatment. 
Animals received 2.5x105 HT-1080 cells via lateral tail vein injection on Day 0 and were 
weighed and scored for clinical signs (scoresheet Supporting information Figure S2) over 21 
days. Animals received 7.5 mg/kg/day of compound (or vehicle) via IP injection from Day -1 to 
Day 20. This dose was selected based on extensive in vivo pharmacokinetic profiling and 
represented a compromise between tolerability and attempting to demonstrate efficacy with 
compounds that show reduced potency against murine uPA.67 
 
 
Figure 10. Effects of amiloride 4, 18 and 26 in experimental mouse model of late-stage lung 
metastasis. All compounds were administered once daily at 7.5 mg/kg/day for 21 days. Lung 
metastasis was quantified by endpoint luciferase assay of lung homogenates. Data represent the 
mean ± SEM (18 and 26 n = 6; Vehicle and 4 n = 4). * = p <0.03; *** = p <0.001 relative to 
vehicle control, ^ = p <0.03 relative to 4.  
 
 30
Amiloride 4 did not significantly inhibit metastasis in this model at the concentration tested. 
Benzofuranyl analog 18 decreased metastasis by 21% (p = 0.0297) relative to control but there 
was no statistically significant difference between amiloride and 18 (Figure 10). 2-Methoxy 
pyrimidine analog 26 significantly decreased lung metastasis (33%, p = 0.0007).  
 
Orthotopic model of pancreatic cancer. The in vivo anti-tumor and anti-metastasis effects 
of 18 and 26 were evaluated alongside the standard of care drug gemcitabine in an orthotopic 
xenograft mouse model of pancreatic cancer (Figure 11). Briefly, female athymic nude mice 
(BALBc nu/nu, 8-11 weeks of age) were anaesthetized and an incision was made in the left flank 
and the spleen and tail of the pancreas were externalized. A mixture of human pancreatic cancer 
cells (AsPC-1) 1×106 and human pancreatic stellate cells (hPSCs) 1×106 in 50µL PBS was 
injected into the tail of the pancreas. uPA expression was confirmed in both cell lines by Western 
Blot analysis (Supporting Information Figure S3).68The pancreas and spleen were then 
reinternalized and the wound closed. Seven days after cell implantation, mice were randomized 
to receive treatment with gemcitabine (75 mg/kg PO twice weekly), 18 or 26 (10 mg/kg IP daily) 
for 28 days (n = 4 mice/group). The higher dose (relative to the lung metastasis model) was 
chosen to increase the likelihood of observing efficacy. In line with previous observations in this 
model, Gemcitabine showed only modest inhibitory effects on the primary tumour.69 
Measurement of tumor volume at endpoint revealed that 18 and 26 produced similar reductions 
to gemcitabine on the primary mass (Figure 11A). Notably, liver metastases (key site in this 
model) were reduced in mice treated with compounds 18 and 26 compared to those treated with 
gemcitabine, with no macroscopic metastatic lesions observed in any mice that received 26 
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(Figure 11B). The absence of liver metastases in all animals treated with 26 was confirmed by 




Figure 11. A) Effects of gemcitabine (Gem), 18 and 26 on endpoint primary tumor volume in an 
orthotopic xenograft pancreatic cancer model. Mice received oral gemcitabine 75 mg/kg twice 
weekly or daily intraperitoneal injections of 18 or 26 (10 mg/kg) for 28 days. Data represent the 
mean ± SEM (n = 4 per group). B) Number of mice with histologically confirmed liver 
metastases after receiving gemcitabine, 18 and 26 (n = 4 per group). *p = 0.0285 vs Vehicle, 
Chi-square test.  
 
CONCLUSIONS 
This study reveals that 6-substituted HMA derivatives are potent inhibitors of human uPA 
with potential for development into a new class of anti-cancer drugs. Access to a diverse series 
of 6-(hetero)aryl analogs was afforded via a simple two step Suzuki-Miyaura/acyl 
guanidinylation approach using commercial boronic acids/esters and a common 6-chloropyrazine 
intermediate 7. The key intermediate was easily synthesized on multigram scale in a single step 
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from commercial reagents. Buchwald-Hartwig chemistry was established on a related 6-
bromopyrazine scaffold to access 6-aminopyrimidine HMA derivative 41. Given the general 
reactivity of halopyrazines in transition metal-catalyzed cross-coupling reactions,70 it is likely 
that a great many other substituents could be appended at the 6-position of HMA using this 
chemistry. Screening of such a library against proteins that reportedly bind to HMA (e.g. P2X7
71, 
NHE172, HIV-1 Vpu73, Influenza A M274, GnRHR75, GABA-A ρ-176, ASIC1a77 and GIRK) 
could help to identify more potent and selective probes for these targets, and possibly therapeutic 
leads.  
Leading compounds from the study showed uPA inhibitory potencies more than 10-fold 
higher than HMA, with X-ray crystallography revealing that the gains arose from interactions 
formed between the appended 6-substituents and uPA’s S1β pocket. High target selectivity was 
demonstrated across the serine hydrolase superfamily and selected analogs showed no activity 
against ENaCs in vitro or K+-sparing/diuretic effects in vivo. Analogs carrying 2-benzofuranyl 
and 5-pyrimidinyl substituents emerged as distinct lead classes with differing physicochemical 
properties and human cell cytotoxicity profiles. Examples from each class were found to inhibit 
formation of lung metastases in a mouse experimental metastasis model, and 2-
methoxypyrimidine analog 26 completely inhibited formation of liver macrometastases in a 
mouse pancreatic cancer model. In summary, this work reports the successful repurposing of the 
diuretic amiloride into potent uPA inhibitors with attractive pharmacological properties for 
further evaluation as a novel class as anti-cancer agents for treating uPA-driven malignancies. 
Experimental 
Chemistry – General. All solvents and chemicals were purchased and used without further 
purification except iPrOH, which was distilled from BaO and stored over 4 Å molecular sieves 
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under Ar. Progress of reactions was monitored using Merck silica gel 60 F254 TLC plates with 
EtOAc/Pet.spirit mixtures as eluent. Compound spots on TLC plates were visualized under UV 
light at 254 nm. Column chromatography was performed using Merck silica gel 60 (230-400 
mesh). Melting points (mp) were measured in open capillaries using a Griffin Analog Melting 
Point Apparatus (Thermo-Fisher Scientific, Waltham, Massachusetts, USA) and are uncorrected. 
1H and 13C NMR spectra were recorded using a Varian Inova 500 or Varian Premium Shielded 
500 (499.74 MHz for 1H; 125.66 MHz for 13C) in deuterated solvents. Chemical shifts are 
reported in parts per million (δ ppm) relative to TMS for 1H or the solvent peak for 13C. High-
resolution mass spectrometry (HRMS) analysis was performed using a Waters XEVO QToF 
mass spectrometer (Waters Corporation, Milford, Massachusetts, USA) with leucine encephalin 
as internal standard. Purity of all final compounds was confirmed at > 95% using high 
performance liquid chromatography (HPLC). HPLC analyses were performed using a Shimadzu 
CLASS-VP LC10 Analytical HPLC system (Shimadzu Corporation, Kyoto, Japan) with 
detection at 254 nm. Gradient elutions were performed using mixtures of solvent 100% 
H2O/0.1% TFA and 100% CH3CN/0.1% TFA on a Waters VisionHT 3 µm C18 column (150 
mm x 4.6 mm) at a flow rate of 0.5 mL.min-1. Column temperature was not controlled. Only one 
previous 6-substituted HMA analog (6-phenyl HMA) has been reported but no characterization 
or uPA inhibition data were described.78 
 
Chemistry – Experimental procedures and compound characterization 
 
Synthesis of methyl 3-amino-6-chloro-5-hexamethyleneimine-2-pyrazinecarboxylate (7).  
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To a suspension of methyl 3-amino-5,6-dichloro-2-pyrazinecarboxylate (5.55 g, 25.0 mmol) in 
2-propanol (50 mL) was added hexamethyleneimine (2.73 g, 3.10 mL, 27.5 mmol). 
Diisopropylethylamine (3.55 g, 4.79 mL, 27.5 mmol) was added and the reaction mixture was 
heated at reflux for 2 hours. The reaction mixture was allowed to cool to room temperature, 
which caused the product to crystallize. The solid product was collected by vacuum filtration and 
washed with cold 2-propanol (2 x 10 mL) and then diethyl ether (10 mL). After drying, the pure 
product was obtained as pink crystals (6.1 g, 86%). mp 109-111 °C; 1H NMR (CDCl3): δ 6.13 
(br s, 2H), 3.89 (s, 3H), 3.82 (t, J = 6.0 Hz, 4H), 1.84 (s, 4H), 1.58 (s, 4H); 13C NMR (CDCl3): δ 
166.4, 153.7, 153.1, 120.3, 111.3, 52.0, 51.1, 28.4, 26.7; MS (ESI): m/z 285 (M+H)+, 307 
(M+Na)+; HRMS (ESI+) Anal. for C12H17N4NaO2
+: Calc. mass 307.0932, found 307.0938. 
 
General Method A: Suzuki-Miyaura coupling reactions 
Methyl 3-amino-6-chloro-5-hexamethyleneimine-2-pyrazinecarboxylate 7 (1 eq.) was 
combined with K2CO3 (10 eq.), the appropriate boronic acid (1.5 eq.) and Pd(PPh3)4 (5 mol%) in 
a two-neck round bottom flask. The flask was connected to a condenser and purged with 
nitrogen. A 4:1 dry toluene: MeOH mixture (60 mL) was added via syringe and the reaction 
mixture was heated at reflux for 0.5-18 h. The mixture was allowed to cool to room temperature 
and filtered through Celite (10 x 3 cm, eluting with 3 x 20 mL EtOAc). The filtrate was 
evaporated to dryness and the residue purified by silica gel flash column chromatography using 
EtOAc/pet spirit. 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(4-(methylthio)phenyl)pyrazine-2-carboxylate (10a) 
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General Method A using 4-(methylthio)phenyl boronic acid (93 mg, 0.545 mmol) afforded 
10a as a yellow solid; yield 77% (104 mg, 0.279 mmol); MP: 132-134 °C; 1H NMR (500 MHz, 
CDCl3) δ 7.42 (d, J = 8.1 Hz, 2H), 7.25 (d, J = 8.1 Hz, 2H), 6.20 (bs, 2H), 3.88 (s, 3H), 3.36 (t, J 
= 5.5 Hz, 4H,), 2.48 (s, 3H), 1.62 (s, 4H), 1.43 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.4, 
154.8, 153.4, 137.8, 137.5, 131.2, 128.3, 126.8, 112.5, 51.9, 51.0, 28.0, 27.1, 16.1; HRESI-MS 
m/z (M + H+), Anal. for C19H25N4O2S: Calc. mass: 373.1698. Found: 373.1688; Anal HPLC 
(70:30 H2O/0.1% TFA:CH3CN/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 36.1 
min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(4-(trifluoromethyl)phenyl)pyrazine-2-carboxylate (11a) 
General Method A using 4-(trifluoromethyl)phenyl boronic acid (570 mg, 3.0 mmol) afforded 
11a as a white solid; yield 64% (505 mg, 1.28 mmol); MP 158-160 °C; 1H NMR (500 MHz, 
CDCl3): δ 7.63 (s, 4H), 6.13 (br s, 2H, NH2), 3.89 (s, 3H), 3.34 (s, 4H), 1.65 (s, 4H), 1.45 (s, 
4H); 13C NMR (126 MHz, CDCl3): δ 167.4, 154.9, 153.7, 144.6, 129.9, 129.3, 128.2, 125.6, 
125.1, 113.2, 52.1, 51.3, 28.1, 27.3;  HRESI-MS m/z (M + Na+) Anal. For C19H21F3N4NaO2: 
Calc. mass 417.1526. Found 417.1514; Anal-HPLC (100% H2O/0.1% TFA→100% 
CH3CN/0.1% TFA over 30 min, tr = 29.3 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(benzo[d][1,3]dioxol-5-yl)pyrazine-2-carboxylate (12a) 
General Method A using benzo[d][1,3]dioxol-5-ylboronic acid (85 mg, 0.515 mmol) afforded 
12a as a yellow solid; yield 51% (66 mg, 0.178 mmol). MP: 156-158 °C; 1H NMR (500 MHz, 
CDCl3) δ 7.02 (s, 1H), 6.93 (d, J = 8.0 Hz, 1H), 6.80 (d, J = 8.0 Hz, 1H), 5.96 (s, 2H), 3.88 (s, 
4H), 3.38 (s, 4H), 1.63 (s, 4H), 1.44 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.6, 154.9, 153.5, 
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147.9, 147.1, 134.9, 131.5, 121.7, 112.2, 108.7, 108.3, 101.1, 51.9, 51.0, 28.1, 27.1; HRESI-MS 
m/z (M + H+) Anal. for C19H23N4O4: Calc. Mass 371.1719. Found 371.1734; Anal HPLC (100 
H2O/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 31.8 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(isoquinolin-4-yl)pyrazine-2-carboxylate (13a) 
General Method A using isoquinolin-4-yl boronic acid (271 mg, 1.06 mmol) afforded 13a as a 
brown solid; yield 58% (156 mg, 0.413 mmol); MP 140-142 °C; 1H NMR (500 MHz, CDCl3) δ 
9.23 (s, 1H), 8.58 (s, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.0 Hz, 1H), 7.68 (t, J = 7.5 Hz, 
1H), 7.62 (t, J = 7.5 Hz, 1H), 3.86 (s, 3H), 3.21 (t, J = 5.5 Hz, 4H), 1.47 (s, 4H), 1.38 (s, 4H); 13C 
NMR (126 MHz, CDCl3) δ 167.3, 155.8, 154.0, 152.1, 143.0, 134.3, 131.8, 130.8, 128.4, 128.0, 
127.4, 126.7, 124.5, 112.9, 52.0, 50.4, 27.8, 26.8; HRESI-MS m/z (M + Na+) 400, Anal. for 
C21H24N5NaO2: Calc. Mass 400.1749. Found 400.1747; Anal HPLC (100% H2O/0.1% 
TFA→100% CH3CN/0.1% TFA over 30 min, tr = 22.3 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-carboxylate (14a)  
General Method A using 1-methyl-1H-pyrazol-4-yl boronic acid (110 mg, 0.526 mmol) 
afforded 14a as a yellow solid; yield 77% (89 mg, 0.269 mmol). MP: 134-136 °C; 1H NMR (500 
MHz, CDCl3) δ 7.64 (s, 1H),  7.57 (s, 1H), 6.17 (bs, 2H), 3.91 (s, 3H), 3.89 (s, 3H), 3.47 (t, J = 6 
Hz, 4H), 1.66 (s, 4H), 1.47 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.4, 155.5, 153.4, 138.7, 
129.1, 125.3, 122.6, 112.4, 52.1, 51.2, 39.0, 28.0, 27.2; HRESI-MS m/z (M + H+) 331, Anal. for 
C16H23N6O2: Calc. Mass 331.1882. Found 331.1894; Anal HPLC (70:30 H2O/0.1% TFA: 





General Method A using 1-(2-morpholinoethyl)-1H-pyrazol-4-yl boronic acid (165 mg, 0.536 
mmol) afforded 15a as a yellow solid; yield 80% (119 mg, 0.277 mmol). MP: 132-134 °C; 1H 
NMR (500 MHz, CDCl3) δ 7.70 (s, 1H), 7.61 (s, 1H), 6.24 (bs, 2H), 4.25 (s, 2H), 3.89 (s, 3H), 
3.69 (s, 4H), 3.46 (s, 4H), 2.84 (s, 2H), 2.50 (s, 4H), 1.65 (s, 4H), 1.47 (s, 4H); 13C NMR (126 
MHz, CDCl3) δ 167.2, 155.5, 153.3, 138.6, 128.7, 125.2, 122.1 112.4, 66.9, 58.2, 53.7, 51.9, 
51.1, 49.6, 27.9 27.0; HRESI-MS m/z (M + H+), Anal. for C22H36N7O3: Calc. mass 430.2567. 
Found 430.2553; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA →100% CH3CN/0.1% 
TFA over 30 min, tr = 21.6 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(1H-indol-2-yl)pyrazine-2-carboxylate (16a) 
General Method A using 1H-indol-2-yl boronic acid (278 mg, 1.73 mmol) afforded 16a as an 
orange solid; yield 34% (87.5 mg, 0.239 mmol). MP 152-154 °C; 1H NMR (500 MHz, CDCl3) δ 
9.14 (s, 1H), 7.57 (d, 1H), 7.37 (d, 1H, J = 7.7 Hz), 7.16 (t, 1H, J = 7.0 Hz), 7.08 (t, 1H, J = 7.0 
Hz), 6.52 (s, 1H), 3.93 (s, 3H), 3.58 (t, J = 5.75 Hz, 4H), 1.70 (s,4H), 1.50 (s, 4H); 13C NMR 
(126 MHz, CDCl3) δ 167.2, 155.1, 153.2, 136.0, 135.7, 129.0, 124.5, 122.4, 120.7, 119.90, 
112.70, 111.0, 102.0, 52.1, 51.7, 28.1, 27.5; HRESI-MS m/z (M + H+) 388, Anal. for 
C20H24N5O2: Calc. mass 388.1730. Found 388.1731; Anal HPLC (100 H2O/0.1% TFA→100% 
CH3CN/0.1% TFA over 30 min, tr = 29.8 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(benzo[b]thiophen-2-yl)pyrazine-2-carboxylate (17a) 
 38
General Method A using benzo[b]thiophen-2-yl boronic acid (534 mg, 3.0 mmol) afforded 
17a as a yellow solid; yield 78% (600 mg); MP 146-148 °C; 1H NMR (500 MHz, CDCl3): δ 1.48 
(s, 4H), 1.69 (s, 4H), 3.51 (s, 4H), 3.91 (s, 3H), 6.13 (br s, 2H, NH2), 7.22 (s, 1H), 7.21 (m, 2H), 
7.71 (d, J = 6.9 Hz, 1H), 7.80 (d, J = 7.0 Hz, 1H); 13C NMR (126 MHz, CDCl3): δ 167.3, 155.3, 
153.6, 143.3, 140.2, 140.1, 125.4, 124.5, 124.4, 123.6, 122.3, 122.0, 113.2, 52.3, 51.3, 28.2, 
27.4; HRESI-MS m/z (M + K+) Anal for C20H22KN4O3  Calc. mass 405.1394. Found 405.1361; 
Anal-HPLC (100 H2O/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 31.9 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(benzofuran-2-yl)pyrazine-2-carboxylate (18a) 
General Method A using benzofuran-2-yl boronic acid (486 mg, 3.0 mmol) afforded 18a as a 
yellow solid; yield 57% (420 mg). MP: 121-123 °C; 1H NMR (500 MHz, CDCl3): δ 1.46 (s, 4H), 
1.66 (s, 4H), 3.45 (t, J = 5.8 Hz, 4H), 3.90 (s, 3H), 6.13 (br s, 2H, NH2), 6.93 (s, 1H), 7.21 (t, J = 
7.3 Hz, 1H), 7.25 (t, J = 7.2 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 7.56 (d, J = 7.5 Hz, 1H); 13C 
NMR (126 MHz, CDCl3): δ 167.2, 164.9, 154.8, 154.6, 129.2, 124.4, 123.1, 121.4, 121.2, 112.9, 
111.5, 105.1, 52.2, 50.2, 28.2, 27.3; HRESI-MS m/z (M + H+) Anal for C20H23N4O2: Calc. mass 
367.1831. Found. 367.1770; Anal-HPLC (70:30 H2O/0.1%: CH3CN/0.1% TFA→100% 
CH3CN/0.1% TFA over 30 min, tr = 29.5 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(4-fluorobenzofuran-2-yl)pyrazine-2-carboxylate (19a) 
General Method A using 4-fluorobenzofuran-2-yl boronic acid (95 mg, 0.531 mmol) afforded 
19a as a yellow solid; yield 58% (80 mg, 0.210 mmol). MP: 108-110 °C; 1H NMR (126 MHz, 
CDCl3): 7.27 (d, 1H), 7.20 (m, 1H), 6.99 (s, 1H), 6.93 (t, 1H, J = 8.5 Hz), 3.91 (s, 3H), 3.46 (s, 4H), 
1.69 (s, 4H), 1.49 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.0, 156.9, 156.2, 154.7, 154.0, 
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138.3, 124.6, 120.5, 118.0, 115.9, 110.4, 108.6, 107.6, 52.2, 50.0, 28.0, 27.1; HRESI-MS m/z (M 
+ Na+) Anal. for C20H21FN6NaO4: Calc. mass 407.1495. Found 407.1504; Anal HPLC (70:30 




General Method A using thiophen-2-yl boronic acid (70 mg, 0.549 mmol) afforded 20a as a 
light yellow solid; yield 85% (99 mg, 0.299 mmol). MP: 118-120 °C; 1H NMR (500 MHz, 
CDCl3) δ 7.27 (d, J = 5 Hz, 1H), 7.03 (d, J = 3 Hz, 1H), 6.98 (m, 1H), 3.89 (s, 3H), 3.43 (t, J = 
5.7 Hz, 4H), 1.67 (s, 4H), 1.47 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.3, 155.2, 153.5, 
142.8, 126.9, 126.0, 125.8, 125.5, 112.7, 52.1, 51.1, 28.2, 27.3; HRESI-MS m/z (M + Na+) Anal. 
for C16H20N4NaO2: Calc. mass 355.1205. Found 355.1193; Anal HPLC (100 H2O/0.1% TFA 
100% CH3CN/0.1% TFA over 30 min, tr = 28.8 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(thiophen-3-yl)pyrazine-2-carboxylate (21a) 
General Method A using thiophen-3-yl boronic acid (75 mg, 0.584 mmol) afforded 21a as a 
white solid; yield 85% (100 mg, 0.302 mmol). MP: 118-120°C; 1H NMR (500 MHz, CDCl3) δ 
7.38 (s, 1H), 7.29 (m, 1H), 7.25 (d, J = 5 Hz, 1H), 3.88 (s, 3H), 3.38 (t, J = 5.8 Hz, 4H), 1.63 (s, 
4H), 1.44 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.4, 155.3, 153.5, 141.3, 128.1, 127.9, 
125.4, 122.8, 112.2, 52.0, 50.9, 28.0, 27.1; HRESI-MS m/z (M + H+) Anal. for C16H21N4NaO2S: 
Calc. mass 355.1205. Found 355.1197; Anal HPLC (100 H2O/0.1% TFA→100% CH3CN/0.1% 
TFA over 30 min, tr = 28.3 min).  
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Methyl 3-amino-5-(azepan-1-yl)-6-(furan-2-yl)pyrazine-2-carboxylate (22a) 
General Method A using furan-2-ylboronic acid (59 mg, 0.526 mmol) afforded 22a as an off 
white solid; yield 98% (111 mg, 0.352 mmol). MP 116-118 °C; 1H NMR (500 MHz, CDCl3): δ 
7.41 (s, 1H), 6.54 (d, J = 2.3 Hz, 1H), 6.45 (s, 1H), 6.13 (br s, 2H, NH2), 3.89 (s, 3H), 3.37 (t, J = 
5.5 Hz, 4H), 1.66 (s, 4H), 1.47 (s, 4H); 13C NMR (126 MHz, CDCl3): δ 167.1, 154.8, 154.0, 
152.2, 141.4, 122.0, 112.1, 111.6, 108.6, 52.0, 50.0, 28.0, 26.9; HRESI-MS m/z (M + Na+) Anal. 
for C16H21N4NaO3: Calc. mass 339.1418. Found 339.1433; Anal-HPLC (100 H2O/0.1% 
TFA→100% CH3CN/0.1% TFA over 30 min, tr = 27.1 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(furan-3-yl)pyrazine-2-carboxylate (23a) 
General Method A using furan-3-yl boronic acid (107 mg, 0.389 mmol) afforded 23a as a 
yellow solid; yield 93% (114 mg, 0.360 mmol). MP: 122-124° C; 1H NMR (500 MHz, CDCl3) δ 
7.64 (s, 1H), 7.41 (s, 1H), 6.61 (s, 1H), 6.20 (bs, 2H), 3.89 (s, 3H), 3.48 (t, J = 5 Hz, 4H), 1.66 (s, 
4H), 1.47 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.3, 155.6, 153.6, 142.6, 140.6, 125.8, 
124.8, 112.6, 111.2, 52.0, 51.0, 28.0, 27.1; HRESI-MS m/z (M + H+) Anal. for C16H21N4O3: Calc. 
mass 316.1614. Found 316.1604; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% 
TFA→100% CH3CN/0.1% TFA over 30 min, tr = 30.9 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(2-fluoropyridin-3-yl)pyrazine-2-carboxylate (24a)  
General Method A using 2-fluoropyridin-3-yl boronic acid (75 mg, 0.529 mmol) afforded 24a 
as a brown solid; yield 76% (92 mg, 0.266 mmol). MP: 156-158°C; 1H NMR (500 MHz, CDCl3) 
δ 8.17 (d, J = 4.3 Hz, 1H), 8.06 (m, 1H), 7.29 (t, J = 5.5 Hz, 1H), 3.89 (s, 3H), 3.36 (s, J = 5.7 
Hz, 4H), 1.63 (s, 4H), 1.46 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.2, 161.3, 155.2, 154.1, 
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146.8, 141.1, 124.5, 123.8, 122.2, 113.3, 52.3, 50.3, 28.1, 27.3; HRESI-MS m/z (M + Na+) Anal. 
for C17H20FN5NaO2: Calc. mass 368.1499. Found 368.1489; Anal HPLC (100 H2O/0.1% 
TFA→100% CH3CN/0.1% TFA over 30 min, tr = 26.3 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(pyrimidin-5-yl)pyrazine-2-carboxylate (25a) 
General Method A using pyrimidin-5-yl boronic acid (279 mg, 2.25 mmol) afforded 25a as a 
yellow solid; yield 91% (450 mg). MP 176-178 °C; 1H NMR (500 MHz, CDCl3): δ 9.13 (s, 1H), 
8.89 (s, 2H), 6.13 (br s, 2H, NH2), 3.91 (s, 3H), 3.52 (t, J = 6.0 Hz, 4H), 1.68 (s, 4H), 1.48 (s, 
4H); 13C NMR (126 MHz, CDCl3): δ 167.1, 157.1, 155.7, 155.3, 153.9, 134.9, 124.5, 114.5, 
52.3, 51.5, 28.0, 27.4; HRESI-MS m/z (M + Na+) Anal. for C16H20N6NaO2: Calc mass 351.1545. 
Found. 351.1535; Anal-HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% CH3CN/0.1% 
TFA over 30 min, tr = 23.4 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(2-methoxypyrimidin-5-yl)pyrazine-2-carboxylate (26a) 
General Method A using 2-methoxypyrimidin-5-yl boronic acid (79 mg, 0.513 mmol) 
afforded 26a as a yellow solid; yield 88% (111 mg, 0.310 mmol). MP 168-170 °C; 1H NMR 
(500 MHz, CDCl3): 8.66 (s, 2H), 6.13 (br s, 2H, NH2), 4.05 (s, 3H), 3.90 (s, 3H), 3.38 (t, J = 5.5 
Hz, 4H), 1.68 (s, 4H), δ 1.48 (s, 4H); 13C NMR (126 MHz, CDCl3): δ 166.4, 164.7, 158.3, 155.3, 
153.8, 128.8, 125.2, 113.9, 55.2, 52.2, 51.4, 28.0, 27.3; HRESI-MS m/z (M + H+) Anal. for 
C17H22N6O3: Calc. mass 359.1832. Found 359.1848; Anal-HPLC (70:30 H2O/0.1% TFA: 






General Method A using 2,4-dimethoxypyrimidin-5-yl boronic acid (79 mg, 0.350 mmol) 
afforded 27a as a yellow solid; yield 91% (124 mg, 0.319 mmol). MP 150-152 °C; 1H NMR 
(500 MHz, CDCl3) δ 8.36 (s, 1H), 4.03 (s, 3H), 3.94 (s, 3H), 3.87 (s, 3H), 3.39 (s, 4H), 1.60 (s, 
4H,), 1.46 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 168.3, 167.2, 164.8, 158.1, 155.3, 154.1, 
123.8, 117.1, 112.6, 55.0, 54.1, 52.0, 50.0, 28.0, 27.0; HRESI-MS m/z (M + H+) Anal. for 
C18H25N6O4 Calc. mass 389.1937. Found389.1929; Anal-HPLC (70:30 H2O/0.1% TFA: 
CH3CN/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 27.1 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(2,6-dimethoxypyridin-3-yl)pyrazine-2-carboxylate (28a) 
General Method A using 2,6-dimethoxypyridin-3-yl boronic acid (200 mg, 0.703 mmol) 
afforded 28a as a yellow solid; yield 42% (115 mg, 0.297 mmol); MP: 134-136 °C; 1H NMR 
(500 MHz, CDCl3) δ 7.66 (d, J = 8.0 Hz, 1H), 6.38 (d, J = 8.0 Hz, 1H), 3.92 (s, 3H), 3.87 (s, 
3H), 3.86 (s, 3H), 3.45 (bs, 2H), 3.31 (bs, 2H), 1.57 (s, 4H), 1.44 (s, 4H); 13C NMR (126 MHz, 
CDCl3) δ 167.5, 162.8, 159.7, 155.3, 153.9, 141.5, 127.6, 116.2, 112.2, 101.3, 53.7, 53.5, 51.9, 
50.1, 28.1, 27.1; HRESI-MS m/z (M + H+), Anal. for C19H25N5O4: Calc. mass 388.1985. Found 
388.1983; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% CH3CN/0.1% TFA 
over 30 min, tr = 31.6 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(2,4-dimethoxyphenyl)pyrazine-2-carboxylate (29a) 
General Method A using 2,4-dimethoxyphenyl boronic acid (128 mg, 0.702 mmol) afforded 
29a as a yellow solid; yield 53% (143 mg, 0.371 mmol). MP: 106-108 °C; 1H NMR (500 MHz, 
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CDCl3): δ 7.33 (d, J = 8.3 Hz, 1H), 6.54 (dd, J = 8.3 Hz, J = 2.1 Hz 1H), 6.42 (d, J = 2.1 Hz, 
1H), 3.85 (s, 3H), 3.82 (s, 3H), 3.70 (s, 3H), 3.44 (s, 2H), 3.26 (s, 2H), 1.58 (s, 2H), 1.53 (s, 2H), 
1.46 (s, 2H), 1.39 (s, 2H); 13C NMR (126 MHz, CDCl3) δ 166.0, 160.9, 158.2, 155.4, 154.0, 
131.1, 129.2, 123.7, 111.8, 105.1, 98.7, 55.7, 55.7, 52.0, 50.6, 27.8, 26.9; HRESI-MS m/z (M + 
Na+), Anal. for C20H27N4NaO4: Calc. mass 409.1852. Found 409.1866; Anal HPLC (100 
H2O/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 28.6 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(3,5-dimethoxyphenyl)pyrazine-2-carboxylate (30a) 
General Method A using 3,5-dimethoxyphenyl boronic acid (128 mg, 0.702 mmol) afforded 
30a as a yellow solid; 62% (166 mg, 0.430 mmol). MP: 96-98 ° C; 1H NMR (500 MHz, CDCl3) 
δ 6.64 (s, 2H), 6.40 (s, 1H), 3.88 (s, 3H), 3.81 (s, 6H), 3.38 (t, J = 6.0 Hz, 4H), 1.64 (s, 4H), 1.44 
(s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.5, 161.0, 154.7, 153.7, 142.8, 131.6, 112.0, 106.3, 
100.0, 55.6, 52.0, 50.9, 28.1, 27.1; HRESI-MS m/z (M + Na+), Anal. for C20H26N4NaO4: Calc. 
mass 409.1852. Found 409.1867; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% 




General Method A using 3,6-dimethoxypyridazin-4-yl boronic acid (97 mg, 0.526 mmol) 
afforded 31a as a yellow solid; yield 68% (94 mg, 0.242 mmol): MP: 152-154 °C; 1H NMR (500 
MHz, CDCl3) δ 7.17 (s, 1H), 4.08 (s, 3H), 4.00 (s, 3H), 3.88 (s, 3H), 3.43 (s, 2H), 3.29 (s, 2H), 
1.63 (s, 4H), 1.44 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 167.00, 162.8, 159.6, 154.7, 154.1, 
135.1, 122.9, 119.4, 113.1, 54.8, 54.6, 52.1, 49.7, 28.0, 27.2; HRESI-MS m/z (M + Na+), Anal. 
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for C18H24N6NaO4: Calc. mass 411.1757. Found 411.1762; Anal HPLC (70:30 H2O/0.1% TFA: 
CH3CN/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 21.2 min). 
 
Methyl 3-amino-6-(2-aminopyrimidin-5-yl)-5-(azepan-1-yl)pyrazine-2-carboxylate (32a) 
General Method A using 2-aminopyrimidin-5-yl boronic acid (208 mg, 1.5 mmol) afforded 
32a as a yellow solid; yield 83% (285 mg). MP: 216-218 °C; 1H NMR (500 MHz, DMSO-d6): δ 
8.27 (s, 2H), 7.04 (br s, 2H, NH2), 6.76 (br s, 2H, NH2), 3.74 (s, 3H), 3.41 (t, J = 5.9 Hz, 4H), 
1.59 (s, 4H), 1.41 (s, 4H); 13C NMR (126 MHz, DMSO-d6): δ 27.0, 27.9, 51.0, 51.9, 112.3, 
123.9, 126.5, 154.2, 155.1, 157.4, 163.0, 167.3, 163.0, 157.4, 155.1, 154.2, 126.5, 123.9, 112.3, 
51.9, 51.0, 27.9, 27.0; HRESI-MS m/z (M + H+), Anal. for  C16H22N7O2: Calc. mass  344.1835. 
Found 344.1833; Anal HPLC (100 H2O/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 
14.2 min). 
 
Methyl 3-amino-5-(azepan-1-yl)-6-(2-chloropyrimidin-5-yl)pyrazine-2-carboxylate (8) 
General Method A using (2-chloropyrimidin-5-yl)boronic acid (475 mg, 3 mmol) afforded 8 
as a yellow solid; (460 mg, 64%); MP 168-170 °C; 1H NMR (CDCl3): δ 8.76 (s, 2H), 6.13 (br s, 
2H, NH2), 3.91 (s, 3H), 3.35 (t, J = 5.8 Hz, 4H), 1.71 (s, 4H), 1.49 (s, 4H); 
13C NMR (CDCl3): δ 
27.3, 27.8, 51.4, 52.2, 114.6, 122.8, 133.3, 153.7, 155.0, 158.0, 159.2, 166.8; MS (ESI): m/z 363 
(M+H)+, 385 (M+H)+; HRESI-MS m/z (M + H+), Anal. for C16H20ClN6O2: Calc. mass  363.1336. 




General Method B: Synthesis of methyl 3-amino-5-(azepan-1-yl)-6-(2-(substituted 
amino)pyrimidin-5-yl)pyrazine-2-carboxylates 33a and 34a  
To a solution of methyl 3-amino-5-(azepan-1-yl)-6-(2-chloropyrimidin-5-yl)pyrazine-2-
carboxylate 8 (0.25 mmol) in DMF (2 mL) at room temperature was added the appropriate amine 
(0.75 mmol). Diisopropylethylamine (0.75 mmol) was then added and the reaction mixture was 
stirred at room temperature for 2 days. The mixture was extracted with EtOAc (3 x 10 mL) and 
the combined organic layer was washed with brine, dried (MgSO4) and evaporated.  The residue 




General Method B using 8 (91 mg, 0.25 mmol) and methylamine (2M in MeOH, 0.375 mL, 
0.75 mmol) gave 33a as a yellow solid; yield 87% (78.0 mg). MP: 158-160 °C. 1H NMR (500 
MHz, CDCl3): δ 8.45 (s, 2H), 6.22 (br s, 2H, NH2), 5.28 (q, J = 4.9 Hz, 1H, NH), 3.90 (s, 3H), 
3.42 (t, J = 5.9 Hz, 4H), 3.04 (d, J = 5.1 Hz, 3H), 1.67 (s, 4H), δ 1.47 (s, 4H); 13C NMR (126 
MHz, CDCl3): δ 167.4, 162.0, 157.2, 155.3, 153.7, 126.9, 124.2, 113.3, 52.3, 51.3, 28.8, 28.0, 
27.3; HRESI-MS m/z (M + H+), Anal. for C17H24N7O2  358.1991, found 358.2001;  Anal HPLC 
(100 H2O/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 14.8 min)  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(2-(isopropylamino)pyrimidin-5-yl)pyrazine-2-
carboxylate (34a)  
General Method B using 8 (91 mg, 0.25 mmol) and isopropylamine (45 mg, 0.75 mmol) gave 
34a as a yellow solid; yield 83% (80 mg). MP: 155-157 °C. 1H NMR (500 MHz, CDCl3): δ 8.43 
 46
(s, 2H), 6.25 (br s, 2H), 5.10 (d, J = 7.8 Hz, 1H), 4.16 (septet, J = 6.8 Hz, 1H), 3.89 (s, 3H), 3.43 
(t, J = 5.9 Hz, 4H), 1.67 (s, 4H), 1.47 (s, 4H), 1.25 (d, J = 7.0 Hz, 6H); 13C NMR (126 MHz, 
CDCl3): δ 167.2, 157.0, 155.1, 153.5, 126.8, 123.8, 113.1, 52.0, 51.1, 43.0, 27.8, 27.1, 22.9; 
HRESI-MS m/z (M + H+), Anal. for for C19H28N7O2  386.2304, found 386.2318; Anal HPLC 
(100 H2O/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 16.1 min)  
Methyl 3-amino-5-(azepan-1-yl)-6-(2-(2-hydroxyethyl)amino)pyrimidin-5-yl)pyrazine-2-
carboxylate (35a)  
To a solution of methyl 3-amino-5-(azepan-1-yl)-6-(2-chloropyrimidin-5-yl)pyrazine-2-
carboxylate 8 (91 mg, 0.25 mmol) in 2-propanol (5 mL) was added ethanolamine (16.8 mg, 
0.017 mL, 0.275 mmol). Diisopropyethylamine (35.5 mg, 0.048 mL, 0.275 mmol) was then 
added and the reaction mixture was heated at reflux for 2 hours. After cooling to room 
temperature, additional equivalents of ethanolamine (0.275 mmol) and DIPEA (0.275 mmol) 
were added and the reaction mixture was heated for a further 2 h. The mixture was allowed to 
cool to room temperature overnight, which caused the product to crystallize. The solid product 
was collected by vacuum filtration and washed with cold 2-propanol (2 x 2 mL) and diethyl ether 
(2 mL). After drying, the pure product was obtained as light yellow crystals (82 mg, 84%).  MP: 
164-166 °C 1H NMR (500 MHz, CDCl3): δ, 8.44 (s, 2H), 6.23 (br s, 2H), 5.64 (t, J = 5.5 Hz, 
1H), 3.90 (s, 3H), 3.85 (t, J = 4.4 Hz, 2H), 3.62 (q, J = 4.9 Hz, 2H), 3.42 (t, J = 5.6 Hz, 4H), 1.68 
(s, 4H), 1.48 (s, 4H); 13C NMR (126 MHz, CDCl3): δ 167.1, 161.7, 156.9, 155.1, 153.5, 126.2, 
124.6, 113.3, 63.6, 52.1, 51.1, 44.9, 27.8, 27.1; HRESI-MS m/z (M + H+), Anal. for C18H26N7O3  
388.2097, found 388.2088; Anal HPLC (100 H2O/0.1% TFA→100% CH3CN/0.1% TFA over 30 
min, tr = 14.4 min). 
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General Method C: Synthesis of acyl guanidines using the reported method
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Free guanidine was generated via neutralization of guanidine.HCl with Na+ iPrO- in iPrOH to create a 
2-fold molar excess relative to the 6-substituted pyrazinoyl methyl ester. A stock solution of iPrO- 
was prepared by adding Na (typically 30-70 mg) in anhydrous iPrOH under N2 and heated at 70 °C 
for 30 min. From this stock solution an amount of iPrO- was removed via syringe and made up to 10 
mL in anhydrous iPrOH. To this solution was added a stoichiometric amount of guanidine 
hydrochloride and the mixture stirred at 70 °C for 30 min. This solution was gravity filtered onto the 
neat 6-substituted pyrazinoyl methyl ester. Once filtration was complete, the mixture was heated to 
reflux and allowed to react for 1-6 h. The reactions were monitored by MS and TLC and terminated 
by removal of solvent under reduced pressure. Final products were isolated by rp-HPLC. All 
compounds were isolated as TFA salts and exchanged to their respective HCl salts by stirring with 
quaternary ammonium Cl- anion exchange resin in MeOH prior to biological evaluation.  
 
General Method D: Improved Synthesis of Acyl Guanidines 
Dry CH3OH (50 mL) was slowly added with stirring to small pieces of sodium (2.3 g, 0.1 
mol) cooled on ice under nitrogen. After complete dissolution of the sodium, guanidine 
hydrochloride (9.55 g, 0.1 mol) was added and the resulting mixture was stirred at room 
temperature for 1.5 h. Filtration of the white precipitate gave a 2 M solution of free guanidine in 
methanol, which was collected in a sealed dry flask under nitrogen and stored in a refrigerator. 
To a suspension of the requisite methyl ester (1 eq, 0.2-0.5 mmol) in DMF (5 mL) was added 2 
M guanidine in methanol (10 eq, 2-5 mmol) and the resulting mixture was stirred at room 
temperature overnight. Brine (20 mL) was added and the mixture extracted with EtOAc (3 x 30 
mL). The organic layer was washed with 10% NaCl (2 x 30 mL), dried (MgSO4), and 
concentrated under reduced pressure. The crude mixture was dissolved in 5 mL of 30% CH3CN: 
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70% H2O and 0.1 % acetic acid and loaded onto a reverse phase silica gel chromatography 
column. Isocratic elution was performed with CH3CN:H2O mixtures containing 0.1 % acetic 
acid). The pooled fractions containing pure compound by TLC analysis were concentrated under 
reduced pressure and neutralised with solid NaHCO3. The aqueous mixture was extracted with 
EtOAc (3 x 30 mL) and the combined organic layer was washed with brine, dried (MgSO4) and 




General Method C using 10a (70 mg, 0.214 mmol) gave 10 as a yellow solid; yield 5% (6 mg, 
0.015 mmol). MP: 152-154 °C; 1H NMR (500 MHz, CDCl3) δ 10.31 (s, 1H), 9.44 (s, 2H), 8.47 
(s, 2H), 7.44 (d, J = 8.1 Hz, 2H), 7.28 (d, J = 8.1 Hz, 2H), 3.40 (t, J = 5.5 Hz, 4H) 1.60 (s, 4H), 
1.46 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 166.0, 156.6, 155.7, 153.6, 139.0, 136.4, 131.2, 
128.1, 126.6, 111.0, 51.5, 27.9, 27.1, 15.5; HRESI-MS m/z (M + H+) Anal for C19H26N7OS: Calc. 
mass 400.1920. Found 400.1935; Anal. HPLC. (70:30 H2O/0.1% TFA: CH3CN/0.1% 




General Method D using 11a (394 mg, 1.0 mmol) gave 11 as a yellow solid; yield 92% (385 
mg). MP 172-175 °C;  1H NMR (CD3OD): δ 7.68 (d, J = 8.0 Hz, 2H), 7.65 (d, J = 8.0 Hz, 2H), 
3.38 (t, J = 5.0 Hz, 4H), 1.65 (s, 4H), 1.46 (s, 4H); 13C NMR (CD3OD): δ 167.9, 160.2, 155.8, 
155.0, 145.6, 130.1, 130.0 (d, J = 32 Hz), 129.2, 125.8 (d, J = 2.7 Hz), 124.3 (d, J = 170), 112.9, 
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51.6, 28.6, 27.6; HRESI-MS m/z (M + H+) Anal for C19H23F3N7O: Calc. mass 422.1916. Found 





General Method C using 12a (54 mg, 0.146 mmol) gave 12 as a yellow oil; yield 9% (6 mg, 
0.015 mmol). MP: 154-156 °C; 1H NMR (500 MHz, DMSO-d6) δ 10.39 (s, 1H), 8.71 (s, 2H), 
8.27 (s, 2H), 7.31 (s, 1H), 6.96 (m, 2H), 6.08 (s, 2H), 3.40 (t, J= 5.75 Hz, 4H), 1.60 (s, 2H), 1.39 
(s, 2H); 13C NMR (126 MHz, DMSO-d6) δ 166.2, 155.2, 154.8, 153.6, 147.26, 146.7, 133.4, 
130.3, 121.4, 112.7, 108.5, 108.0, 101.2, 50.4, 27.2, 26.1; HRESI-MS m/z (M + H+) Anal for 
C19H24N7O3: Calc. mass 398.1941. Found 398.1929; Anal. HPLC (70:30 H2O/0.1% TFA: 




General Method C using 13a (156 mg, 0.413 mmol) gave 13 as an orange solid; yield 15% 
(32 mg, 0.079 mmol). MP 158-160 °C; 1H NMR (500 MHz, CD3OD) δ 10.47 (s, exchange with 
solvent), 9.57 (bs, 1H), 9.19 (s, exchange with solvent), 9.09 (s, exchange with solvent) 8.69 (bs, 
1H), 8.40 (d, J = 8.2 Hz, 1H), 8.01 (t, J = 7.5 Hz, 1H), 7.91 (t, J = 7.5 Hz, 1H), 7.81 (d, J = 8.2 
Hz, 1H), 3.37 (s, 2H), 3.23 (s, 2H), 1.53 (s, 4H), 1.44 (s, 4H); 13C NMR (126 MHz, CD3OD) δ 
167.5, 157.7, 156.9, 156.4, 149.7, 137.6, 136.9, 136.9, 136.8, 131.6, 131.4, 129.0, 125.7, 124.7, 
113.0, 51.6, 29.0, 27.8; HRESI-MS m/z (M + H+)  Anal for C20H24N7OS: Calc. mass 410.1763. 
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Found 410.1758; Anal. HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% CH3CN/0.1% 
TFA over 30 min, tr 22.7 min).  
 
3-Amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(1-methyl-1H-pyrazol-4-yl)pyrazine-2-
carboxamide (14)  
General Method C using 14a (69 mg, 0.207 mmol) gave 14 as a yellow oil; yield 38% (32 mg, 
0.193 mmol). MP 150-152 °C; 1H NMR (500 MHz, CDCl3) δ 10.49 (s, 1H), 8.83 (s, 2H), 8.52 
(s, 2H), 8.00 (s, 1H), 7.57 (s, 1H), 5.49 (bs, 2H), 3.93 (s, 3H), 3.50 (t, J = 5.75 Hz, 4H), 1.69 (s, 
4H), 1.49 (s, 4H);13C NMR (126 MHz, CDCl3) δ 166.6, 156.4, 156.1, 153.4, 137.4, 130.7, 125.1, 
121.7, 111.1, 51.5, 38.7, 27.9, 27.3; HRESI-MS m/z (M + H+)  Anal for C16H24N9O: Calc. mass 
358.2104. Found 358.2118; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% 




General Method C using 15a (99 mg, 0.229 mmol) gave 15 as an orange oil; yield 20% (22 
mg, 0.048 mmol). MP: 157-159 °C; 1H NMR (500 MHz, CDCl3) δ 10.48 (s, 1H), 8.86 (s, 2H), 
8.65 (s, 2H), 7.89 (s, 1H), 7.56 (s, 1H), 4.67 (s, 2H), 3.93 (s, 4H), 3.69 (s, 2H,), 3.47 (s, 4H), 3.42 
(bs, 2H), 3.05 (bs, 2H,) 1.67 (s, 4H), 1.49 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 166.6, 156.4, 
156.1, 153.6, 140.0, 130.6, 124.1, 122.9, 111.3, 63.8, 57.2, 53.3, 51.4, 46.4, 27.9, 27.2; HRESI-
MS m/z (M + H+) Anal for C21H33N10O2: Calc. mass 457.2788. Found 457.2796; Anal. HPLC 




General Method C using 16a (76 mg, 0.209 mmol) gave 16 as an orange solid; yield 31% (29 
mg, 0.074 mmol). MP 152-154 °C; 1H NMR (500 MHz, CDCl3) δ 11.09 (s, 1H), 10.82 (s, 1H), 
8.82 (s, 2H), 7.92 (s, 2H), 7.55 (d, 1H, J = 7.7 Hz), 7.41 (d, 1H, J = 7.7 Hz), 7.12 (t, 1H, J = 7 
Hz), 7.03 (t, 1H), 6.44 (s, 1H), 3.64 (t, J = 5.0 Hz, 4H), 1.73 (s, 4H), 1.50 (s, 4H); 13C NMR (126 
MHz, CDCl3) δ 166.7, 156.2, 155.7, 153.0, 136.6, 134.9, 128.3, 125.7, 122.7, 120.5, 119.8, 
111.7, 110.8, 102.3, 52.1, 27.9, 27.6; HRESI-MS m/z (M + H+) Anal for C20H28N7O3: Calc. mass 
393.2151. Found 393.2159; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% 




General Method D using 17a (383 mg, 1.0 mmol) gave 17 as a yellow solid; yield 78% (320 
mg); MP 220-224 °C; 1H NMR (500 MHz, CDCl3) δ 10.48 (s, 1H), 8.92 (s, 2H), 8.76 (s, 2H), 
7.60 (d, J = 7.5 Hz, 1H), 7.43 (d, J = 7.5 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 7.26 (t, J = 7.5 Hz, 
1H), 7.20 (s, 1H), 3.50 (t, J = 5.75 Hz, 4H), 1.69 (s, 4H), 1.49 (s, 4H); 13C NMR (126 MHz, 
CDCl3) δ 168.2. 164.9, 160.7, 156.5, 155.4, 144.1, 141.3, 141.2, 125.8, 125.5, 124.7, 123.5, 
123.0, 113.5, 52.0, 29.2, 28.1; HRESI-MS m/z (M + H+) C20H24N7OS: Calc. mass 410.1763. 






General Method D using 18a (366 mg, 1.0 mmol) gave 18 as a yellow solid; yield 86% (338 
mg). MP 130-132 °C ; 1H NMR (CD3OD): δ 7.64 (d, J = 7.5 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 
7.31 (t, J = 8.0 Hz, 1H), 7.26 (t, J = 7.5 Hz, 1H), 7.05 (s, 1H), 3.51 (t, J = 5.0 Hz, 4H), 1.71 (s, 
4H), 1.54 (s, 4H); 13C NMR (CD3OD): δ 167.4, 164.3, 154.6, 154.5, 154.4, 154.1, 129.7, 124.9, 
123.7, 121.6, 121.1, 112.4, 111.5, 105.6, 50.3, 28.6, 27.3; HRESI-MS m/z (M + H+) Anal for 
C20H24N7O2: Calc. mass 394.1991. Found 394.1986; Anal HPLC (100% H2O/0.1% TFA→100% 




General Method C using 19a (54 mg, 0.139 mmol) gave 19 as an orange solid; yield 26% (15 
mg, 0.036 mmol). MP: 132-136°C; 1H NMR (500 MHz, CD3OD) δ 10.47 (s, exchange with 
solvent), 8.98 (s, exchange with solvent), 8.33 (s, exchange with solvent), 7.36 (t, J = 8.7Hz, 
1H), 7.32 (q, J = 5.5Hz, 1H), 7.22 (s, 1H), 7.02 (t, J = 8.7Hz, 1H), 3.44 (t, J = 5.8 Hz, 4H) 1.72 
(s, 4H), 1.51 (s, 4H); 13C NMR (126 MHz, CD3OD) δ 167.3, 158.2, 157.4, 157.0, 156.9, 156.2, 
156.2, 155.7, 126.6, 121.2, 112.2, 109.8, 108.7, 102.4, 51.1, 29.0, 27.9; HRESI-MS m/z (M + 
H+) Anal for C20H22FN7O2,: Calc. mass  412.1897. Found  412.1909; Anal HPLC (70:30 
H2O/0.1% TFA: CH3CN/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr 25.6 min).  
 
3-Amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(thiophen-2-yl)pyrazine-2-carboxamide (20) 
General Method C using 20a (99 mg, 0.298 mmol) gave 20 as a yellow oil; yield 2% (2 mg, 
0.006 mmol). MP 136-138 °C; 1H NMR (500 MHz, CDCl3) δ 10.10 (s, 1H), 10.04 (bs, 2H), 8.08 
(bs, 2H), 7.26 (d, J = 5 Hz, 1H), 7.03 (d, J = 3 Hz, 1H), 3.47 (t, J = 5.75 Hz, 4H), 1.68 (m, 4H), 
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1.49 (m, 4H); 13C NMR (126 MHz, CDCl3) δ 167.0, 156.3, 156.1, 153.4, 139.9, 128.4, 128.2, 
125.2, 124.5, 111.0, 51.0, 27.8, 27.1; HRESI-MS m/z (M + H+) Anal for C16H21N7O: Calc. mass 
360.1607. Found 360.1610; Anal. HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% 
CH3CN/0.1% TFA over 30 min, tr 24.2 min).  
 
3-Amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(thiophen-3-yl)pyrazine-2-carboxamide (21) 
General Method C using 21a (103 mg, 0.309 mmol) gave 21 as an orange oil; yield 17% (24 
mg, 0.067 mmol). MP: 138-140 °C; 1H NMR (500 MHz, CDCl3) δ 10.31 (s, 1H), 8.62 (bs, 2H), 
8.29, (bs, 2H), 7.78 (m, 3H), 7.64 (dd, J = 8.5, 1.5 Hz, 1H,), 7.44 (m, 2H), 6.23 (bs, 2H), 3.38 (t, 
J = 5.75, 4H), 1.59 (s, 4H), 1.42 (s, 4H); 13C NMR (126 MHz, CDCl3) δ 166.7, 156.2, 156.0, 
153.6, 140.1, 128.4, 127.8, 125.9, 123.6, 110.7, 51.3, 27.9, 27.1; HRESI-MS m/z (M + H+) Anal 
for C16H21N7O: Calc. mass 360.1607. Found 360.1611; Anal HPLC (70:30 H2O/0.1% TFA: 
CH3CN/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 25.2 min).  
 
3-Amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-yl)pyrazine-2-carboxamide (22) 
General Method D using 22a (316 mg, 1.0 mmol) gave 22 as a yellow solid; yield 91% (310 
mg). MP 143-146 °C; 1H NMR (CD3OD): δ 7.50 (s, 1H), 6.55 (d, J = 3.0 Hz, 1H), 6.50 (s, 1H), 
3.37 (t, J = 6.0 Hz, 4H), 1.64 (s, 4H), 1.47 (s, 4H); 13C NMR (CD3OD): δ 168.1, 160.7, 156.3, 
156.0, 153.4, 142.8, 122.4, 112.6, 112.4, 109.9, 50.9, 29.2, 27.8. HRESI-MS m/z (M + H+) Anal 
for C16H22N7O2: Calc. mass 344.1835. Found 344.1830; Anal HPLC (100% H2O/0.1% 




General Method C using 23a (90 mg, 0.285 mmol) gave 23 as a yellow solid; yield 35% (41 
mg, 0.119 mmol). MP 146-148 °C; 1H NMR (500 MHz, CDCl3) δ 10.42 (s, 1H), 8.54 (s, 4H), 
7.63 (s, 1H), 7.42 (s, 1H), 6.63 (s, 1H), 5.35 (bs, 2H), 3.52 (t, J = 5.75 Hz, 4H), 1.68 (s, 4H), 1.49 
(s, 4H); 13C NMR (126 MHz, CDCl3) δ 166.4, 156.3, 155.8, 153.6, 143.2, 141.1, 125.3, 124.9, 
110.8, 110.7, 51.4, 27.9, 27.1; HRESI-MS m/z (M + H+) Anal for C16H22N7O2: Calc. mass 
344.1835. Found 344.1837; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% 
CH3CN/0.1% TFA over 30 min, tr 25.5 min). 
 
3-Amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(2-fluoropyridin-3-yl)pyrazine-2-
carboxamide (24)  
General Method C using 24a (100 mg, 0.290 mmol) gave 24 as a yellow solid; yield 13% (18 
mg, 0.048 mmol). MP 160-162 °C; 1H NMR (500 MHz, CDCl3) δ 10.42 (s, 1H), 8.59 (bs, 4H), 
8.17 (m, 2H), 7.29 (t, J = 5.4 Hz) 5.13 (bs, 2H), 3.38 (s, 4H), 1.64 (s, 4H), 1.47 (s, 4H); 13C 
NMR (126 MHz, CDCl3) δ 166.5, 160.7, 158.8, 156.0, 155.9, 154.0, 146.9, 141.4, 124.2, 123.4, 
122.5, 111.8, 50.4, 27.9, 27.2; HRESI-MS m/z (M + H+) Anal for C17H22FN8O: Calc. mass 
373.1901. Found 373.1916; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% 
CH3CN/0.1% TFA over 30 min, tr 22.2 min). 
 
3-Amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(pyrimidin-5-yl)pyrazine-2-carboxamide (25) 
General Method D using 25a (328 mg, 1.0 mmol) gave 25 as a yellow solid; yield 87% (305 
mg). MP 188-190 °C; 1H NMR (CD3OD): δ 8.98 (s, 1H), 8.97 (s, 2H), 3.35 (t, J = 5.5 Hz, 4H), 
1.67 (s, 4H), 1.47 (s, 4H); 13C NMR (CD3OD): δ 162.2, 156.5, 156.3, 155.7, 155.5, 154.0, 153.5, 
135.2, 122.2, 51.0, 28.0, 27.1; HRESI-MS m/z (M + H+). Anal for C16H22N9O: Calc. mass 
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356.1947.Found 356.1942; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% 




General Method D using 26a (358 mg, 1.0 mmol) gave 26 as a yellow solid; yield 90% (345 
mg). MP: 148-150 °C; 1H NMR (CD3OD): δ 8.77 (s, 2H), 4.08 (s, 3H), 3.46 (t, J = 5.5 Hz, 4H), 
1.72 (s, 4H), 1.54 (s, 4H); 13C NMR (CD3OD): δ 166.7, 164.1, 163.4, 158.1, 154.8, 153.6, 128.6, 
124.2, 112.8, 54.3, 27.7, 26.7; HRESI-MS m/z (M + H+) Anal for C17H24N9O2: Calc. mass 
386.2053. Found 386.2048; Anal HPLC (100% H2O/0.1% TFA→100% CH3CN/0.1% TFA over 




General Method C using 27a (104 mg, 0.267 mmol) gave 27 as a yellow solid; yield 54% (65 
mg, 0.156 mmol). MP: 184-186 °C; 1H NMR (CD3OD) δ 10.76 (s, 1H), 9.27 (s, 2H), 8.51 (s, 
2H), 8.48 (s, 2H), 4.08 (s, 3H), 3.35 (t, J = 5.75 Hz, 4H), 1.66 (s, 4H), 1.46 (s, 4H). 13C NMR 
(126 MHz, CDCl3) δ 166.6, 164.0, 157.8, 156.1, 153.9, 127.8, 124.7, 112.5, 55.6, 51.6, 27.8, 
27.1; HRESI-MS m/z (M + H+) Anal for C18H26N9O3: Calc. mass 416.2159. Found 416.2158; 
Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, 





General Method C using 28a (98 mg, 0.253 mmol) gave 28 as a yellow solid; yield 13% (15 
mg, 0.036 mmol). MP: 152-154° C; 1H NMR (500 MHz, CDCl3) δ 10.28 (s, 1H), 8.77 (s, 2H), 
8.14 (s, 2H), 7.61 (d, J = 8.0 Hz), 6.39 (d, J = 8.0 Hz, 1H), 3.94 (s, 3H), 3.87 (s, 3H), 3.52 (s, 
2H), 3.35 (s, 2H), 1.60 (s, 4H), 1.51 (s, 2H), 1.44 (s, 2H); 13C NMR (126 MHz, CDCl3) δ 166.0, 
163.2, 159.2, 155.4, 153.5, 141.1, 128.0, 114.6, 110.2, 101.3, 53.8, 53.5, 50.4, 27.7, 26.81; 
HRESI-MS m/z (M + H+) Anal for C19H27N8O3: Calc. mass 415.2206. Found 415.2191; Anal 
HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr 
26.1 min).  
 
3-Amino-5-(azepan-1-yl)-N-carbamimidoyl-6-(2,4-dimethoxyphenyl) pyrazine-2-
carboxamide (29)  
General Method C using 29a (123 mg, 0.317 mmol) gave 29 as a yellow solid; yield 8% (12 
mg, 0.029 mmol). MP: 156-158 °C; 1H NMR (500 MHz, CDCl3) δ 10.19 (s, 1H), 9.10 (bs, 2H), 
7.79 (bs, 2H), 7.23 (d, J = 8.1 Hz), 6.58 (d, J = 8.1 Hz), 6.48 (s, 1H) 3.86 (s, 3H), 3.74 (s, 3H), 
3.51 (s, 2H), 3.36 (s, 2H), 1.59 (s, 4H), 1.50 (s, 2H), 1.45 (s, 2H); 13C NMR (126 MHz, CDCl3) δ 
166.0, 161.5, 157.8, 155.7, 155.4, 153.8, 130.6, 129.6, 122.1, 109.8, 105.0, 98.7, 55.7, 55.6, 50.6, 
27.8, 26.9; HRESI-MS m/z (M + H+) Anal for C20H28N7O3: Calc. mass 414.2254. Found 
414.2269; Anal. HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→100% CH3CN/0.1% TFA 




carboxamide (30)  
General Method C using 30a (147 mg, 0.381 mmol) gave 30 as a yellow solid; yield 26% (44 
mg, 0.116 mmol). MP: 138-140 °C; 1H NMR (500 MHz, CDCl3) δ 10.75 (s, 1H), 8.81 (bs, 2H), 
8.60 (bs, 2H), 6.73 (d, J = 2.2 Hz), 6.58 (t, J = 2.2 Hz, 1H), 3.84 (s, 6H), 3.38 (s, 2H), 1.64 (s, 
4H), 1.45 (s, 2H); 13C NMR (126 MHz, CDCl3) δ 167.0, 160.1, 156.4, 155.6, 153.8, 141.6, 
132.9, 110.9, 106.5, 100.3, 55.9, 51.0, 28.0, 27.1; HRESI-MS m/z (M + H+) Anal for 
C20H28N7O3: Calc. mass 414.2254. Found 414.2244; Anal. HPLC (70:30 H2O/0.1% TFA: 




General Method C using 31a (94 mg, 0.243 mmol) gave 31 as a yellow solid; yield 17% (21 
mg, 0.051 mmol). MP 202-204 °C; 1H NMR (500 MHz, CD3OD) δ 10.38 (s, exchange with 
solvent), 8.77 (s, exchange with solvent), 8.21 (s, exchange with solvent), 7.35 (s, 1H), 4.06 (s, 
3H), 3.99 (s, 3H), 3.35 (s, 4H), 1.66 (s, 4H), 1.55 (s, 2H), 1.45 (s, 2H); 13C NMR (126 MHz, 
CD3OD) δ 167.3, 164.1, 160.9, 156.9, 156.8, 156.1, 136.3, 124.0, 121.4, 112.2, 55.4, 55.3, 51.0, 
28.9, 27.9; HRESI-MS m/z (M + H+) Anal for C18H26N9O3: Calc. mass 416.2159. Found  
416.2150; Anal HPLC (70:30 H2O/0.1% TFA: CH3CN/0.1% TFA→00% CH3CN/0.1% TFA 





General Method D using 32a (86 mg, 0.25 mmol) gave 32 as a yellow solid; yield 78% (72 
mg). MP 225-228; 1H NMR (DMSO-d6): δ 1.41 (s, 4H), 1.60 (s, 4H), 3.38 (t, J = 5.9 Hz, 4H), 
6.73 (br s, 2H), 7.25 (br s, 1H), 8.40 (s, 2H); 13C NMR (DMSO-d6): δ 167.5, 162.9, 159.1, 
157.5, 154.9, 153.7, 126.0, 123.6, 112.9, 51.1, 28.0, 27.0; HRESI-MS m/z (M + H+), Anal for 
C16H23N10O3: Calc. mass 371.2056. Found 371.2067; Anal. HPLC (100% H2O/0.1% 




General Method D using 33a (39 mg, 0.11 mmol) gave 33 as a yellow solid; yield 85% (36 
mg). MP 168-170; 1H NMR (CD3OD): δ  8.47 (s, 2H), 3.48 (t, J = 5.6 Hz, 4H), 2.97 (s, 3H), 1.69 
(s, 4H), 1.51 (s, 4H); 13C NMR (CD3OD): δ 28.0, 28.5, 29.0, 52.0, 113.5, 124.4, 127.3, 155.4, 
156.7, 158.3, 158.5, 162.9, 168.3, 162.9, 158.5, 158.3, 156.7, 155.4, 127.3, 124.4, 113.5, 52.0, 
29.0, 28.5, 28.0; HRESI-MS m/z (M + H+) Anal for C17H25N10O: Calc. mass  385.2213, Found 





General Method D using 34a (35 mg, 0.09 mmol) gave 34 as a yellow solid; yield 89% (32 
mg). MP: 172-175 °C; 1H NMR (CD3OD): δ  8.46 (s, 2H), 4.14 (septet, J = 6.8 Hz, 1H), 3.47 (t, 
J = 5.6 Hz, 4H), 1.69 (s, 4H), 1.51 (s, 4H), 1.25 (d, J = 6.5 Hz, 6H); 13C NMR (CD3OD): δ 21.6, 
26.8, 27.8, 42.8, 50.9, 112.3, 123.2, 126.2, 154.2, 155.5, 157.1, 158.8, 160.6, 167.1, 160.6, 158.8, 
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157.1, 155.5, 154.2, 126.2, 123.3, 112.3, 50.9, 42.8, 27.8, 26.8, 21.6;  HRESI-MS m/z (M + H+) 
Anal for C19H29N10O: Calc. mass 413.2526, Found 413.2525; Anal. HPLC (100% H2O/0.1% 




General Method D using 35a (50 mg, 0.13 mmol) gave 35 as a Yellow solid: yield 86% (46 mg). 
MP: 188-191 °C; 1H NMR (CD3OD): δ 8.48 (s, 2H), 3.72 (t, J = 5.6 Hz, 2H), ), 3.54 (t, J = 5.6 
Hz, 2H), 3.45 (t, J = 5.8 Hz, 4H), 1.68 (s, 4H), 1.50 (s, 4H); 13C NMR (CD3OD): δ 167.1, 162.3, 
160.8, 158.2, 156.3, 154.9, 126.5, 124.7, 117.5, 61.7, 51.9, 44.6, 28.9, 27.8.; HRESI-MS m/z (M 
+ H+) Anal for C18H27N10O2: Calc. mass 415.2318.Found  415.2324;  Anal. HPLC (100% 




To a stirred solution of 7 (2.85 g, 10 mmol) and DMAP (61 mg, 0.5 mmol) in 1,2-dichloroethane 
(40 mL) was added a solution of di-tert-butyl dicarbonate (6.57 g, 30 mmol) in 1,2-
dichloroethane (20 mL) at rt. The reaction mixture was heated at 70 °C for 18 h. After cooling to 
room temperature, additional equivalents of di-tert-butyl dicarbonate (3.28 g, 15 mmol) and 
DIPEA (10 mL) were added and the reaction mixture was heated for a further 18 h. Solvents 
were evaporated and the residue was partitioned between EtOAc (100 mL) and water (100 mL). 
The aqueous layer was extracted with EtOAc (3 x 75 mL) and the combined organic layer was 
washed with brine, dried (MgSO4) and concentrated. The residue was purified by silica gel flash 
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column chromatography using EtOAc/pet spirit (10-15%) to give 36 (4.10 g, 85%) as a white 
solid; MP: 116-118 °C; 1H NMR (CDCl3): δ 3.89 (s, 3H), 3.88 (t, J = 6.1 Hz, 4H), 1.55 (s, 4H), 
1.84 (s, 4H), 1.41 (s, 18H); 13C NMR (CDCl3): δ 163.0, 152.3, 150.4, 145.4, 128.6, 126.1, 83.3, 
52.8, 51.6, 28.1, 28.1, 26.7; MS (ESI): m/z  507 (M+Na)+; HRESI-MS m/z (M + H+) Anal for 
C22H33ClN4O6Na: Calc. mass 507.1986. Found 507.2000; Anal. HPLC (100% H2O/0.1% 
TFA→100% CH3CN/0.1% TFA over 30 min).Methyl 5-(azepan-1-yl)-3-((tert-
butoxycarbonyl)amino)pyrazine-2-carboxylate (37) 
To a mixture of chloropyrazine 36 (3.30 g, 6.8 mmol), Pd/C (476 mg, 10 mol%) and MgO (408 
mg, 10.2 mmol) was added dry MeOH (50 mL). The flask was charged with H2 (1 atm) and the 
reaction mixture was stirred at rt for 2 days. The solvent was evaporated and the residue 
redissolved in EtOAc and filtered through Celite, eluting with EtOAc. The organic layer was 
washed with brine, dried (MgSO4) and evaporated to give the crude mono Boc-protected product 
37 as a white solid (2.22 g, 92%). Crude product showed sufficient purity and was used in the 
next step with further purification; MP: 97-100 °C; 1H NMR (400 MHz, CDCl3) δ 10.28 (s, 1H), 
7.68 (s, 1H), 3.94 (s, 3H), 3.62 (br s, 4H), 1.58 (br s, 4H), 1.53 (s, 9H), 1.84 (br s, 4H); 13C NMR 
(CDCl3): δ 167.3, 153.8, 150.6, 150.3, 122.4, 113.5, 80.7, 52.3, 47.9, 28.3, 27.4, 26.6; HRESI-
MS m/z (M + H+) Anal for C17H27N4O4: 351.2032. Found 351.2032. Anal. HPLC (100% 




To a solution of pyrazine methyl ester 37 (2.10 g, 6.0 mmol) in CH2Cl2 (90 mL) was added N-
bromosuccinimide (1.18 g, 6.6 mmol) and the reaction mixture was stirred at rt for 5 h. The 
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mixture was treated with water (50 mL) and stirred for 10 min. The organic layer was separated, 
washed with sodium bicarbonate solution (2 x 50 mL) and brine (50 mL), dried (MgSO4) and 
concentrated. The residue was purified by silica gel flash column chromatography using  
EtOAc/pet spirit (10-15%) to give 38  (1.56 g, 60%) as a white solid; MP: 114-115 °C; 1H NMR 
(CDCl3): δ 10.04 (s, 1H), 3.95 (t, J = 6.0 Hz, 4H), 3.92 (s, 3H), 1.89 (br s, 4H), 1.60 (t, J = 3.1 
Hz, 4H), 1.52 (s, 9H); 13C NMR (CDCl3): δ 166.3, 153.0, 150.0, 147.7, 114.8, 111.9, 81.0, 52.5, 
51.4, 28.2, 28.2, 26.8; MS (ESI): m/z  429 (M+H)+; HRESI-MS m/z (M + Na+) Anal for 
C17H25BrN4O4Na: Calc. mass 451.0957. Found 451.0959. Anal. HPLC (100% H2O/0.1% 
TFA→100% CH3CN/0.1% TFA over 30 min).  
Methyl 5-(azepan-1-yl)-3-((tert-butoxycarbonyl)amino)-6-(pyrimidin-2-ylamino)pyrazine-
2-carboxylate (39) 
A re-sealable Schlenk tube was charged with bromopyrazine 38 (429 mg, 1.0 mmol), 2-
aminopyrimidine (135 mg, 1.4 mmol), Pd2(dba)3 (10 mg, 0.011 mmol, 1 mol % Pd), Xantphos 
(13 mg, 0.022 mmol), Cs2CO3 (426 mg, 1.4 mmol) and degassed dioxane (5 mL). The Schlenk 
tube was capped and carefully subjected to three cycles of evacuation-backfilling with N2. It was 
then sealed and the reaction mixture heated at 100 °C for 20 h. The mixture was cooled to rt, 
diluted with THF (20 mL), filtered through Celite and concentrated. The residue was purified by 
silica gel flash column chromatography using EtOAc/pet spirit  (50-60%) to give 39 (130 mg, 
30%) as a white solid; MP: 168-170 °C; 1H NMR (CDCl3): δ 10.16 (s, 1H), 8.35 (d, J = 4.8 Hz, 
2H), 7.23 (s, 1H), 6.71 (t, J = 4.8 Hz, 1H), 3.90 (s, 3H), 3.77 (t, J = 6.0 Hz, 4H), 1.73 (br s, 4H), 
1.53 (s, 9H), 1.48 (br s, 4H); 13C NMR (CDCl3): δ 166.8, 161.3, 158.3, 152.3, 150.2, 147.9, 
126.6, 113.2, 111.5, 80.5, 52.4, 50.5, 28.3, 28.0, 26.8; MS (ESI): m/z 444 (M+H)+; HRESI-MS 
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m/z (M + H+) Anal for C21H30N7O4: Calc. mass 444.2359. Found 444.2374. Anal. HPLC (100% 
H2O/0.1% TFA→100% CH3CN/0.1% TFA over 30 min).  
 
Methyl 3-amino-5-(azepan-1-yl)-6-(pyrimidin-2-ylamino)pyrazine-2-carboxylate (40) 
To a solution of Boc-protected pyrazine 39 (60 mg, 0.135 mmol) in CH2Cl2 (4 mL) at 0 °C was 
added TFA (0.1 mL) and the mixture was stirred at room temperature overnight. The mixture 
was concentrated in vacuo and the residue partitioned between CH2Cl2 (20 mL) and saturated 
NaHCO3 solution (20 mL). The organic layer was dried (MgSO4) and concentrated and the 
residue purified by silica gel flash column chromatography using EtOAc/pet spirit (60-70%) to 
give 40 (45 mg, 98%) as a grey solid; MP: 194-196 °C; 1H NMR (CDCl3): δ 8.34 (d, J = 4.8 Hz, 
2H), 7.04 (s, 1H), 6.67 (t, J = 4.8 Hz, 1H), 6.20 (br s, 2H, NH2), 3.87 (s, 3H), 3.67 (t, J = 6.0 Hz, 
4H), 1.69 (br s, 4H), 1.48 (t, J = 3.2 Hz, 4H); 13C NMR (CDCl3): δ 166.8, 161.8, 158.4, 154.2, 
153.5,  124.3, 112.8, 109.4, 52.0, 50.6, 50.3, 28.2, 26.7; HRESI-MS m/z (M + H+) Anal for 
C16H22N7O2: Calc. mass 344.1835. Found 344.1848. Anal. HPLC (100% H2O/0.1% 




General Method D using 40 (35 mg, 0.1 mmol) gave 41 (30 mg, 81%) as a yellow solid: MP: 
210-212 °C; 1H NMR (CD3OD): δ  8.25 (d, J = 4.9 Hz, 2H), 6.70 (t, J = 4.9 Hz, 1H), 3.70 (t, J = 
6.0 Hz, 4H), 1.63 (br s, 4H), 1.43 (t, J = 3.1 Hz, 4H); 13C NMR (CD3OD): δ  165.7, 162.2, 158.3, 
155.6, 154.9, 154.8, 124.1, 112.3, 108.0, 50.4, 27.8, 26.2; MS (ESI): m/z  371 (M+H)+; HRESI-
 63
MS m/z (M + H+) Anal for C16H23N10O: Calc. mass 371.2056. Found 371.2057; Anal HPLC 
(100% H2O/0.1% TFA→100% CH3CN/0.1% TFA over 30 min, tr = 14.3 min). 
 
Cell culture conditions. ATCC certified cell lines were used for all experiments. Cells were 
cultured at 37 °C, 95% humidity and 5% (v/v) CO2 in a ThermoScientific Heracell 150i CO2 
incubator (ThermoScientific) and maintained in DMEM/Hi Glucose culture medium 
supplemented with 10% heat-inactivated FCS. Adherent cells were passaged via the addition of 
trypsin/0.05% EDTA solution (GIBCO), followed by centrifugation and resuspension in fresh 
media using a 5 mL Luerlock syringe fitted with an 18-gauge needle (Terumo, Tokyo, Japan). 
All cell lines were obtained from ATCC certified stocks and routinely tested for the presence of 
mycoplasma infection. 
 
Fluorometric uPA activity assay. Urokinase from human kidney cells (Cat # U4010, Sigma-
Aldrich, St. Louis, MI, USA) was diluted to 900 nM, aliquoted and stored at -80 °C until use in 
experiments (typically 4-5 plates assayed on the same day). Thawed enzyme stocks were 
maintained at -20 °C between during assays using a Nalgene Labtop Cooler Jr (Cat# 5115-0012, 
Thermo-Fisher Scientific, Waltham, Massachusetts, USA). A 5 mM stock solution of Urokinase 
fluorescent substrate III (Z-Gly-Gly-Arg-AMC, Calbiochem Cat # 672159, Merck Millipore, 
Massachusetts, USA, Human uPA Km = 400 µM) was prepared in dH2O/10% DMSO and 
aliquoted with storage at -20 °C. Assay buffer (20 mM HEPES pH 7.4, 100 mM NaCl, 0.5 mM 
EDTA, 0.01% v/v Tween-20) was prepared and used within 7 days with storage at 4 °C. On the 
day of assay, compound stocks (20-50 mM in anhydrous DMSO) were serially diluted in assay 
buffer in a clear Greiner CELLSTAR® 96-well plate on ice (Greiner Bio-One GmBH, 
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Kremsmünster, Austria) to give each dilution at 2X the final assayed concentration. In a separate 
black Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH, Kremsmünster, Austria), 
residual volumes of assay buffer were added via multichannel pipette to compound fluorescence 
blanks and inhibited enzyme control wells, as appropriate. Next, 90 µL of dilute fluor (250 µM 
final) was added to all wells, followed by 100 µL of 2x compound dilution to appropriate wells. 
Immediately prior to assay, 900 nM uPA stock was diluted to 15 nM and 10 µL of this dilution 
was added to all relevant wells, initiating the reaction. Reaction progress was monitored using a 
POLARStar OMEGA fluorescence plate reader (Fluorescence intensity mode, top-optic, ex. 355 
nm em. 450 nm, 20 flashes per well, double orbital shaking for 3s prior to every read, cycle time 
60 s, 45-60 cycles, incubation at 37 °C, BMG-Labtech, Ortenberg, Germany). Changes in 
fluorescence over a 15 minute period from the linear portion of the reaction progress curve were 
used to determine IC50 values by fitting log-transformed data to a sigmoidal dose-response curve 
in GraphPad PRISM v7.0 (GraphPad Software, La Jolla, CA, USA). Experiments with Mouse 
uPA (Active Mouse Urokinase, HMW, Molecular Innovations Inc., Michigan, USA) were 
performed as above with a final enzyme concentration of 20 nM (Km = 580). Ki values were 
calculated according to the methods of Cheng and Prussof.54 
Chromogenic Trypsin-like serine protease (TLSP) activity assays. For experiments using 
uPA (Cat # U4010, Sigma-Aldrich, St. Louis, MI, USA), trypsin, tPA, thrombin, plasmin and 
Factor Xa, concentrated stocks were prepared in deionized H2O and stored at -80 °C until thawed 
for use. Thawed enzyme stocks were maintained at -20 °C between assays using a Nalgene 
Labtop Cooler Jr (Cat# 5115-0012, Thermo-Fisher Scientific, Waltham, Massachusetts, USA). A 
312.5 µM stock solution of S-2288 chromogenic substrate (H-D-Ile-L-Pro-L-Arg-p-nitoraniline, 
Chromogenix, Massachusettes, USA, uPA Km = 200 µM, trypsin Km = 28 µM, tPA Km = 300 
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µM, thrombin Km = 3 µM, plasmin Km = 9 mM) was prepared in deionized H2O and aliquoted 
with storage at -20 °C. Assay buffer (10 mM HEPES, 150 mM NaCl, 0.01% v/v Tween-20, pH 
7.4) was prepared and used within 7 days with storage at 4 °C. On the day of assay, compound 
stocks (20-50 mM in DMSO) were serially diluted in assay buffer in a clear Greiner 
CELLSTAR® 96-well plate on ice (Greiner Bio-One GmBH, Kremsmünster, Austria) to give 
each dilution at 10X the final assay concentration. In a separate Greiner CELLSTAR® 96-well 
plate (Greiner Bio-One GmBH, Kremsmünster, Austria) residual volumes of assay buffer were 
added via multi-channel pipette to compound fluorescence blanks and inhibited enzyme control 
wells, as appropriate. Next, 80 µL of dilute substrate (250 µM final) was added to all wells, 
followed by 10 µL of 10x compound dilution to appropriate wells. Immediately prior to assay, 
concentrated enzyme stocks were diluted to 100 nM and 10 µL of this dilution was added to all 
relevant wells, initiating the reaction (Final enzyme concentration = 10 nM). DMSO was present 
at a final concentration of 1% v/v. Change in absorbance over time at 405 nm was measured at 
37 °C using a Molecular Devices SpectraMax Plus 384-well plate reader (Molecular Devices 
LLC, Sunnyvale, California, USA). IC50 values were determined by plotting percentage of 
residual activity (V0) versus log drug concentration and fitted to sigmoidal dose response curves 
using GraphPad PRISM v7.0 (GraphPad Software, La Jolla, CA, USA). The following 
chromogenic substrates and final enzyme concentrations were used for experiments with other 
TLSPs. S-2366, L-pyroGlu-L-Pro-L-Arg-p-nitroaniline, Chromogenix, Massachusettes, USA, 
[Human plasma kallikrein] = 23.5 nM, Km = 430 µM, [Factor XIa] = 2 nM, Km = 400 µM, 
[Activated protein C] = 10 nM, Km = 200 µM.  
Crystallization and X-ray Data Collection. Expression and purification of recombinant 
human uPA protease domain was performed as previously described79. Crystals were grown by 
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the sitting drop vapor diffusion method and were obtained by equilibrating against a reservoir 
solution containing 50 mM sodium citrate (pH 4.6) and 2.0 M ammonium sulfate supplemented 
with 5% PEG400 at room temperature for a period of 3 days. For uPA:inhibitor co-complexes at 
pH 7.4, the crystals were soaked for one week in new soaking buffer (40% PEG4000, 100 mM 
Tris-HCl pH 7.4) containing 100 µM compound. Prior to X-ray data collection, crystals were 
soaked in a cryoprotectant solution containing 20% glycerol and snap-frozen in liquid N2. X-ray 
diffraction data of the crystals were collected at the BL17U beamline, Shanghai Synchrotron 
Radiation Facility (SSRF). The diffraction data was indexed and integrated using the HKL2000 
program package80. Structures were solved by molecular replacement81 using the uPA structure 
(PDB code: 4DVA)82 as the search model. The electron density for the compound was clearly 
visible in the uPA active sites and was modelled based on the Fo-Fc difference map. The 
structures was refined using the ccp4 program package80 and manually adjusted using the 
molecular graphics program COOT83 iteratively until convergence. Solvent molecules were 
added using a Fo-Fc Fourier difference map at 2.5 σ in the final refinement step. Statistics for 
data collection and final model refinement are summarized in the Supporting Information Table 
S1. 
  
EnPlex assays. Enplex superfamily-wide serine hydrolase activity screening was performed as 
described in reference 56. 
 
Cytotoxicity assays. Sub-confluent cells (~70-80% confluence) were harvested and 
dissociated into a single cell suspension. Cells were seeded at a density of 5000 cells/well (final 
volume 90 µl) into a Greiner CELLSTAR® 96-well plate (Greiner Bio-One GmBH, 
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Kremsmünster, Austria) via multichannel pipette and incubated for 18h prior to the addition of 
compounds. Compounds were serially diluted from 20-50 mM DMSO stocks in culture media in 
a separate 96-well plate under sterile conditions to give 10x stocks (10 nM-1 mM) on the day of 
compound addition. 10 µL of the 10x compound/media stocks or matched vehicle/media 
solutions (for vehicle controls; final vehicle concentration was equal to 0.2%) were transferred 
via multichannel pipette into the assay plate containing 90 µL cell suspension via multichannel 
pipette to give the treated assay plate at the final 1X drug concentrations (1 nM-100  µM, n = 4 
wells at each concentration). Drug blanks or vehicle media blanks were included as appropriate 
at each concentration to correct for intrinsic color of the compounds and the Phenol Red 
containing media. 200 µL media was added to outside wells to decrease evaporation but were not 
used in the assay itself. Compound-treated plates were incubated for 48h prior to development. 
After 48h, plates were removed from the incubator and 20 µL CellTitre 96® Aqueous One 
Solution Cell Proliferation Assay (Cat # G3581, Promega Corporation, Fitchburg, Wisconsin, 
USA) was added to each well. Plates were incubated for a further 2h prior to reading at 490 nm 
using a SpectraMax Plus 384-well plate reader (Molecular Devices LLC, Sunnyvale, California, 
USA). IC50 values (defined as the concentration of each treatment causing 50% inhibition of 
maximal cell viability) were determined using a logarithmic sigmoidal dose-response curve 
using the variable slope parameter to determine IC50 using GraphPad PRISM v7.0 (GraphPad 
Software, La Jolla, CA, USA). 
 
ENaC inhibition assays. HEK-293 Cells were cultured in Dulbecco’s Modified Eagle 
Medium/Nutrient Mixture F-12 (D-MEM/F-12) supplemented with 10% fetal bovine serum, 100 
U/mL penicillin G sodium, 100 µg/mL streptomycin sulfate and appropriate selection antibiotics. 
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Semi-confluent cells were transfected with cDNA for ENaC α, β and γ subunits (genes 
SCNN1A, SCNN1B and SCNN1G) prior to experimentation. Cells were plated at a density of 
20,000 cells/well in a 384-well black wall, flat clear bottom microtiter plates (Type: BD Biocoat 
Poly-D-Lysine Multiwell Cell Culture Plate) and incubated at 37 ºC overnight. Following 
manufacturer instructions, cells were loaded with 20 µL of membrane potential dye solution for 
30 min at 37 °C from the FLIPR Membrane Potential Red Dye Fluorescence Assay Kit 
(Molecular Devices, Sunnyvale, California, USA). This assay uses fluorometric detection of 
changes in membrane potential following modulation of transmembrane ion channel/exchanger 
activity; i.e. antagonism of stimulated ENaC activity in this case. Drug, vehicle and control 
solutions were prepared from frozen stocks in DMSO on the day of experimentation through 
dilution into HEPES-buffered physiological salt solution (NaCl 137 mM, KCl 4 mM, CaCl2 1.8 
mM, MgCl2 1 mM, HEPES 10 mM, Glucose 10 mM, DMSO 0.3% v/v, pH 7.4) in a 384-well 
microtiter plate ready for addition to the assay plate by the FLIPRTETRA instrument. All analogs 
were tested at 8 concentrations (n = 4 wells at each concentration). Positive control cells were 
stimulated with 1 µM S-3969 (ENaC agonist, n = 4 wells)84. Negative control cells were first 
stimulated with 1 µM S-3969 and then treated with 30 µM benzamil (potent ENaC antagonist, n 
= 4 wells). Following dye loading, cells were pre-incubated with 5 µL drug, vehicle or control 
solutions for 5 min. Next 5 µL of S-3939 solution (final [S-3969] = 1 µM) was added to 
stimulate ENaC activity. All data were normalized to agonist-treated positive and antagonist-
treated negative controls such that the agonist-treated signal corresponded to 100% activity and 
antagonist-treated signal corresponded to 0% activity. Normalized data were used to determine 
IC50 values for each analog using the log[inhibitor]-normalized response variable slope algorithm 
in GraphPad PRISM v7.0 (GraphPad Software, La Jolla, California, USA). These experiments 
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were performed under contract by Charles River Laboratories, Cleveland, Ohio, USA. 
 
Rat diuresis and kaliuresis model. Sixty-four male 21 week old Sprague-Dawley rats were 
randomised into 8 groups of 8 animals. All test animals received one intraperitoneal (IP) 
injection of either vehicle or 25 mg/kg Acetazolamide followed by one intravenous (IV) 
injection of vehicle, 1.5 mg/kg Amiloride or 1.5 mg/kg Amiloride derivative. Acetazolamide was 
administered at an injection volume of 1 ml/kg and concentration of 25 mg/ml. Amiloride, 
HMA, 18 and 26 were administered at an injection volume of 1 ml/kg and concentration of 1.5 
mg/ml. Monosodium acetazolamide was formulated in 0.9% saline. Amiloride and HMA were 
formulated in 50 mM acetate buffer (pH 5.5)/5% v/v DMSO, 18 and 26 were formulated in 50 
mM acetate buffer (pH 5.5)/5% v/v DMSO/0.5% v/v Tween-80. Immediately following dosing, 
all animals were placed into metabolic cages and total urine collected over 6 h. A control group 
receiving IP and IV administrations of vehicle was also included for comparison. Urine Na+ and 
K+ levels were quantitated using a Konelab 20 XTi Biochemistry Analyzer (LLQ = 20 mM). 
This experiment was approved by the Austin Health Animal Ethics Committee (A2016/05420) 
and was conducted in accordance with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes, 7th Edition, 2004. Statistical analyses were performed using a 
one-way ANOVA with Dunnett’s post-hoc test in GraphPad PRISM v7.0 (GraphPad Software, 
La Jolla, California, USA). 
 
Mouse lung metastasis model. All animal studies were approved by the Institutional Animal 
Care and Use Committee at the University of Wollongong (AE1708). Male and female NOD.Cg-
Prkdc<scid>IL2rg<tm1Wjl>SzJAusb mice (Australian BioResources, Moss Vale, NSW, 
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Australia) at 7-8 weeks of age were randomized into treatment groups (n = 4-6/treatment group). 
Treatments commenced one day prior to tail vein administration of 2.5 ×105 luciferase-tagged 
HT-1080 human fibrosarcoma cells (BioWare Brite HT-1080-Red-Fluc) in an injection volume 
of 100 uL PBS [Except sham control (n = 1)]. Daily IP injections continued to day 20 with 7.5 
mg/kg amiloride, 18, 26 or vehicle (50 mM acetate buffer pH 5.5, 7.5% v/v DMSO, 0.75% 
Tween-80). Animals were weighed and assessed for clinical signs daily. Humane endpoints of 
>15% acute weight loss (from previous 7 day maximum individual weight) or >20% chronic 
weight loss (from all-time individual maximum weight) or a body condition score >3 were 
employed. On day 21, all remaining animals were euthanized via slow CO2 asphyxiation, 
weighed, necropsied and had their lungs removed. Lungs were snap frozen in liquid N2 and 
stored at -80 ˚C until homogenization. Lungs were homogenized on ice using a PRO Scientific 
Bio-Gen PRO200 Homogenizer in cell lysis buffer (150 mM NaCl, 10 mM Tris Base, 1% Triton 
X100 v/v, pH 8.0) and centrifuged twice at 4 ˚C and 1,000 rpm for 15 min to remove cell debris. 
Homogenates were prepared to approximately 50 mg/mL protein based on individual wet lung 
weights. Luciferase activity was quantified according to the manufacturer’s instructions using the 
Molecular Diagnostics SpectraMax Glo Steady-Luc Report Assay Kit. Luciferase assays were 
conducted in clear-bottomed white walled 96 well plates (Nunc) using a BMG Labtech 
PolarSTAR multimode plate reader. Data were analysed using GraphPad PRISM v7.0 and 
statistical significance determined using the one-way ANOVA with Dunnett’s Post-hoc test.  
 
Orthotopic model of pancreatic cancer. The orthotopic model has been described in detail 
previously.69, 85 In brief, 6–8-week-old female athymic nude mice (BALB/c nu/nu) were 
anaesthetised and an incision was made in the left flank, followed by exteriorisation of the spleen 
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and tail of the pancreas. A mixture of human PC cells (AsPC-1) 1 × 106 + human PSCs (hPSCs) 
1 × 106 in 50 µl PBS was injected into the tail of the pancreas. AsPC-1 cells were chosen for their 
high implantation rate (100% in our hands) and high reproducibility of tumor growth rates and 
metastasis. After intra-pancreatic injection, organs were reinternalized and the abdomen 
surgically closed. Mice receiving treatment were randomised into subgroups (n = 4 mice per 
group) on postsurgical day 7. These mice were treated as follows for 4 weeks:  Gemcitabine 
(75 mg/Kg BIW oral gavage); 18 or 26 (10 mg/kg/day IP or Vehicle (daily IP, BIW oral gavage). 
Compounds were formulated for IP injection in 50 mM sodium acetate buffer (pH 5.5)/10% 
(v/v) DMSO/1% (w/v/) Kolliphor HS-15 and filtered through 0.22 µm PVDF syringe-driven 
filters under sterile conditions. Pancreatic tumor growth was monitored by palpation. Mice were 
killed at 4 weeks after first IP injection. Tumors were resected and assessed for size and volume 
by two separate observers (tumor volume was calculated to two decimal points, according to an 
established formula (1/2(length × breadth × width) using digital Vernier calipers (Intech tools, 
Thomas town, VIC, Australia)85. The abdominal cavity, mesentery, spleen, liver and lungs were 
examined and scored according to the presence or absence of visible macrometastatic nodules. 
these organs were then excised and fixed in 10% neutral buffered formalin overnight and 
processed using the Leica Peloris Dual Retort tissue processor (Germany). Histological staining 
was performed on 4µm sections deparaffinised in xylene and rehydrated using graded ethanol 
washes. Haematoxylin and Eosin staining were performed on a Leica Autostainer XL. 
 This experiment was approved by the University of New South Wales Animal Care and 






The Supporting Information is available free of charge on the ACS Publications website at DOI: 
XXXXX 
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ABBREVIATIONS USED 
 ABPP, Activity-based protein profiling; ASIC1a, Acid-sensing ion channel 1a; C1r, 
complement C1r subcomponent; C1s, Complement component 1s; DDHD1, Phosphatidic acid-
preferring phospholipase A1; DIPEA, Diisopropylethylamine; DOCA, Deoxycorticosterone 
acetate; DPP7, Dipeptidyl peptidase 2; ENaC, Epithelial sodium channel; FLT3-ITD+, Fms-like 
tyrosine kinase internal tandem duplication positive; GABA-A, γ-aminobutyric acidA receptor; 
Gem , Gemcitabine; GIRK, G protein-coupled inwardly-rectifying potassium channel; GnRHR, 
Gonadotropin-releasing hormone receptor; GPCR, G protein-coupled receptor; hA2AAR-WT, 
Human adenosine A2A receptor; HER2, Human epidermal growth factor receptor 2; HIV-1, 
Human immunodeficiency virus 1; HMA, 5- (N,N-hexamethylene) amiloride; Hpsc, Human 
pancreatic stellate cells; KLKb1, Plasma kallikrein;  LACTB, Serine beta-lactamase-like protein; 
NECA, 5’-(N-ethylcarboxamido)adenosine; NHE1, Sodium hydrogen exchanger isoform 1; NSB 
Non-specific binding; P2X7, P2X purinoreceptor; PRCP, prolylcarboxypeptidase; SOSA, 
Selective optimization of side-activity; SAR, Structure-activity relationship; SAPE, Streptavidin-
phycoerythrin; TB, total binding; TLSP, Trypsin-like serine protease; TMPRSS11d, Trypsin and 
transmembrane protease serine 11D; uPA, Urokinase plasminogen activator; uPAR, Urokinase 




1. Ulisse, S.; Baldini, E.; Sorrenti, S.; D'Armiento, M., The urokinase plasminogen activator 
system: a target for anti-cancer therapy. Curr. Cancer. Drug. Targets. 2009, 9 (1), 32-71. 
2. Brungs, D.; Chen, J.; Aghmesheh, M.; Vine, K. L.; Becker, T. M.; Carolan, M. G.; 
Ranson, M., The urokinase plasminogen activation system in gastroesophageal cancer: A 
systematic review and meta-analysis. Oncotarget 2017, 8 (14), 23099-23109. 
3. Croucher, D. R.; Saunders, D. N.; Lobov, S.; Ranson, M., Revisiting the biological roles 
of PAI2 (SERPINB2) in cancer. Nat. Rev. Cancer. 2008, 8 (7), 535-545. 
4. Harris, N. L. E.; Vennin, C.; Conway, J. R. W.; Vine, K. L.; Pinese, M.; Cowley, M. J.; 
Shearer, R. F.; Lucas, M. C.; Herrmann, D.; Allam, A. H.; Pajic, M.; Morton, J. P.; Australian 
Pancreatic Cancer Genome, I.; Biankin, A. V.; Ranson, M.; Timpson, P.; Saunders, D. N., 
SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer. Oncogene 2017, 
36 (30), 4288-4298. 
5. Yang, J. L.; Seetoo, D.; Wang, Y.; Ranson, M.; Berney, C. R.; Ham, J. M.; Russell, P. J.; 
Crowe, P. J., Urokinase-type plasminogen activator and its receptor in colorectal cancer: 
independent prognostic factors of metastasis and cancer-specific survival and potential 
therapeutic targets. Int J Cancer 2000, 89 (5), 431-439. 
6. Harris, L.; Fritsche, H.; Mennel, R.; Norton, L.; Ravdin, P.; Taube, S.; Somerfield, M. R.; 
Hayes, D. F.; Bast, R. C., Jr., American society of clinical oncology 2007 update of 
recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 2007, 25 (33), 
5287-5312. 
7. Look, M. P.; van Putten, W. L.; Duffy, M. J.; Harbeck, N.; Christensen, I. J.; Thomssen, 
C.; Kates, R.; Spyratos, F.; Ferno, M.; Eppenberger-Castori, S.; Sweep, C. G.; Ulm, K.; Peyrat, J. 
P.; Martin, P. M.; Magdelenat, H.; Brunner, N.; Duggan, C.; Lisboa, B. W.; Bendahl, P. O.; 
Quillien, V.; Daver, A.; Ricolleau, G.; Meijer-van Gelder, M. E.; Manders, P.; Fiets, W. E.; 
Blankenstein, M. A.; Broet, P.; Romain, S.; Daxenbichler, G.; Windbichler, G.; Cufer, T.; 
Borstnar, S.; Kueng, W.; Beex, L. V.; Klijn, J. G.; O'Higgins, N.; Eppenberger, U.; Janicke, F.; 
Schmitt, M.; Foekens, J. A., Pooled analysis of prognostic impact of urokinase-type plasminogen 
activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer. Inst. 2002, 94 
(2), 116-128. 
8. Foekens, J. A.; Peters, H. A.; Look, M. P.; Portengen, H.; Schmitt, M.; Kramer, M. D.; 
Brunner, N.; Janicke, F.; Meijer-van Gelder, M. E.; Henzen-Logmans, S. C.; van Putten, W. L.; 
Klijn, J. G., The urokinase system of plasminogen activation and prognosis in 2780 breast cancer 
patients. Cancer. Res. 2000, 60 (3), 636-643. 
9. Duffy, M. J.; O'Grady, P.; Devaney, D.; O'Siorain, L.; Fennelly, J. J.; Lijnen, H. J., 
Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. 
Cancer 1988, 62 (3), 531-533. 
10. Estreicher, A.; Muhlhauser, J.; Carpentier, J. L.; Orci, L.; Vassalli, J. D., The receptor for 
urokinase type plasminogen activator polarizes expression of the protease to the leading edge of 
migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell. Biol. 
1990, 111 (2), 783-792. 
11. Lund, I. K.; Illemann, M.; Thurison, T.; Christensen, I. J.; Hoyer-Hansen, G., uPAR as 
anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-
based therapy. Curr. Drug. Targets. 2011, 12 (12), 1744-1760. 
 75
12. Dohn, L. H.; Illemann, M.; Høyer-Hansen, G.; Christensen, I. J.; Hostmark, J.; 
Litlekalsoy, J.; von der Maase, H.; Pappot, H.; Laerum, O. D., Urokinase-type plasminogen 
activator receptor (uPAR) expression is associated with T-stage and survival in urothelial 
carcinoma of the bladder. Urol. Oncol. 2015, 33 (4), 165.e15-24. 
13. Ploug, M.; Ellis, V., Structure-function relationships in the receptor for urokinase-type 
plasminogen activator. Comparison to other members of the Ly-6 family and snake venom 
alpha-neurotoxins. FEBS Lett. 1994, 349 (2), 163-168. 
14. Duffy, M. J.; Duggan, C., The urokinase plasminogen activator system: a rich source of 
tumour markers for the individualised management of patients with cancer. Clin. Biochem. 2004, 
37 (7), 541-548. 
15. Rowe, R. G.; Weiss, S. J., Navigating ECM barriers at the invasive front: the cancer cell-
stroma interface. Annu. Rev. Cell. Dev. Biol. 2009, 25, 567-595. 
16. Matthews, H.; Ranson, M.; Kelso, M. J., Anti-tumour/metastasis effects of the potassium-
sparing diuretic amiloride: an orally active anti-cancer drug waiting for its call-of-duty? Int. J. 
Cancer. 2011, 129 (9), 2051-2061. 
17. Ranson, M.; Andronicos, N. M., Plasminogen binding and cancer: promises and pitfalls. 
Front. Biosci. 2003, 8, s294-304. 
18. Ngo, J. C.; Jiang, L.; Lin, Z.; Yuan, C.; Chen, Z.; Zhang, X.; Yu, H.; Wang, J.; Lin, L.; 
Huang, M., Structural basis for therapeutic intervention of uPA/uPAR system. Curr. Drug. 
Targets. 2011, 12 (12), 1729-1743. 
19. Tyndall, J. D.; Kelso, M. J.; Clingan, P.; Ranson, M., Peptides and small molecules 
targeting the plasminogen activation system: towards prophylactic anti-metastasis drugs for 
breast cancer. Recent. Pat. Anticancer. Drug. Discov. 2008, 3 (1), 1-13. 
20. Towle, M. J.; Lee, A.; Maduakor, E. C.; Schwartz, C. E.; Bridges, A. J.; Littlefield, B. A., 
Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new 
class of selective synthetic urokinase inhibitor. Cancer. Res. 1993, 53 (11), 2553-2559. 
21. Xing, R. H.; Mazar, A.; Henkin, J.; Rabbani, S. A., Prevention of breast cancer growth, 
invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase 
inhibitor B-428. Cancer. Res. 1997, 57 (16), 3585-3593. 
22. Alonso, D. F.; Tejera, A. M.; Farias, E. F.; Bal de Kier Joffe, E.; Gomez, D. E., Inhibition 
of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase 
inhibitor B428. Anticancer. Res. 1998, 18 (6a), 4499-4504. 
23. Nienaber, V. L.; Davidson, D.; Edalji, R.; Giranda, V. L.; Klinghofer, V.; Henkin, J.; 
Magdalinos, P.; Mantei, R.; Merrick, S.; Severin, J. M.; Smith, R. A.; Stewart, K.; Walter, K.; 
Wang, J.; Wendt, M.; Weitzberg, M.; Zhao, X.; Rockway, T., Structure-directed discovery of 
potent non-peptidic inhibitors of human urokinase that access a novel binding subsite. Structure 
2000, 8 (5), 553-563. 
24. Wendt, M. D.; Geyer, A.; McClellan, W. J.; Rockway, T. W.; Weitzberg, M.; Zhao, X.; 
Mantei, R.; Stewart, K.; Nienaber, V.; Klinghofer, V.; Giranda, V. L., Interaction with the S1 
beta-pocket of urokinase: 8-heterocycle substituted and 6,8-disubstituted 2-naphthamidine 
urokinase inhibitors. Bioorg. Med. Chem. Lett. 2004, 14 (12), 3063-3068. 
25. Wendt, M. D.; Rockway, T. W.; Geyer, A.; McClellan, W.; Weitzberg, M.; Zhao, X.; 
Mantei, R.; Nienaber, V. L.; Stewart, K.; Klinghofer, V.; Giranda, V. L., Identification of novel 
binding interactions in the development of potent, selective 2-naphthamidine inhibitors of 
urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution. J. Med. 
Chem. 2004, 47 (2), 303-324. 
 76
26. Bruncko, M.; McClellan, W. J.; Wendt, M. D.; Sauer, D. R.; Geyer, A.; Dalton, C. R.; 
Kaminski, M. A.; Weitzberg, M.; Gong, J.; Dellaria, J. F.; Mantei, R.; Zhao, X.; Nienaber, V. L.; 
Stewart, K.; Klinghofer, V.; Bouska, J.; Rockway, T. W.; Giranda, V. L., Naphthamidine 
urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. Bioorg 
Med. Chem. Lett. 2005, 15 (1), 93-98. 
27. Rockway, T. W.; Giranda, V. L., Inhibitors of the proteolytic activity of urokinase type 
plasminogen activator. Curr. Pharm. Des. 2003, 9 (19), 1483-1498. 
28. Frederickson, M.; Callaghan, O.; Chessari, G.; Congreve, M.; Cowan, S. R.; Matthews, J. 
E.; McMenamin, R.; Smith, D. M.; Vinkovic, M.; Wallis, N. G., Fragment-based discovery of 
mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. 
J. Med. Chem. 2008, 51 (2), 183-186. 
29. Sturzebecher, J.; Vieweg, H.; Steinmetzer, T.; Schweinitz, A.; Stubbs, M. T.; Renatus, 
M.; Wikstrom, P., 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg. Med. Chem. 
Lett. 1999, 9 (21), 3147-3152. 
30. Heinemann, V.; Ebert, M. P.; Laubender, R. P.; Bevan, P.; Mala, C.; Boeck, S., Phase II 
randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in 
combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, 
locally advanced pancreatic cancer. Br. J. Cancer. 2013, 108 (4), 766-770. 
31. AG, W., Positive Phase II data for MESUPRON® in breast cancer. Wilex Half-Yearly 
Financial Report 2012 2012. 
32. Spinar, J.; Spinarova, L.; Vitovec, J., Diuretics in monotherapy and in combination with 
other diuretics and nondiuretics in the treatment of hypertension. Vnitr. Lek. 2013, 59 (6), 486-
494. 
33. Lant, A. F.; Smith, A. J.; Wilson, G. M., Clinical evaluation of amiloride, a potassium-
sparing diuretic. Clin. Pharmacol. Ther. 1969, 10 (1), 50-63. 
34. Kleyman, T. R.; Cragoe, E. J., Jr., The mechanism of action of amiloride. Semin. 
Nephrol. 1988, 8 (3), 242-248. 
35. Palmer, B. F., Regulation of Potassium Homeostasis. Clin. J. Am. Soc. Nephrol. 2015, 10 
(6), 1050-1060. 
36. Jankun, J.; Keck, R. W.; Skrzypczak-Jankun, E.; Swiercz, R., Inhibitors of urokinase 
reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer. 
Res. 1997, 57 (4), 559-563. 
37. Vassalli, J. D.; Belin, D., Amiloride selectively inhibits the urokinase-type plasminogen 
activator. FEBS Lett. 1987, 214 (1), 187-191. 
38. Perazella, M. A., Drug-induced hyperkalemia: old culprits and new offenders. Am. J. 
Med. 2000, 109 (4), 307-314. 
39. Wermuth, C. G., Selective optimization of side activities: another way for drug 
discovery. J. Med. Chem. 2004, 47 (6), 1303-1314. 
40. Matthews, H.; Ranson, M.; Tyndall, J. D.; Kelso, M. J., Synthesis and preliminary 
evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA). 
Bioorg. Med.Chem. Lett. 2011, 21 (22), 6760-6766. 
41. Kleyman, T. R.; Cragoe, E. J., Jr., Amiloride and its analogs as tools in the study of ion 
transport. J. Membr. Biol. 1988, 105 (1), 1-21. 
42. Song, C. W.; Lyons, J. C.; Makepeace, C. M.; Griffin, R. J.; Cragoe, E. J., Jr., Effects of 
HMA, an analog of amiloride, on the thermosensitivity of tumors in vivo. Int. J. Radiat. Oncol. 
Biol. Phys. 1994, 30 (1), 133-139. 
 77
43. Luo, J.; Tannock, I. F., Inhibition of the regulation of intracellular pH: potential of 5-
(N,N-hexamethylene) amiloride in tumour-selective therapy. Br. J. Cancer. 1994, 70 (4), 617-
624. 
44. Rich, I. N.; Worthington-White, D.; Garden, O. A.; Musk, P., Apoptosis of leukemic cells 
accompanies reduction in intracellular pH after targeted inhibition of the Na(+)/H(+) exchanger. 
Blood 2000, 95 (4), 1427-1434. 
45. Man, C. H.; Lam, S. S.; Sun, M. K.; Chow, H. C.; Gill, H.; Kwong, Y. L.; Leung, A. Y., 
A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-
ITD+ AML. Blood 2014, 123 (16), 2530-2539. 
46. Ye, J. H.; Gao, J.; Wu, Y. N.; Hu, Y. J.; Zhang, C. P.; Xu, T. L., Identification of acid-
sensing ion channels in adenoid cystic carcinomas. Biochem. Biophys. Res. Commun. 2007, 355 
(4), 986-992. 
47. Rowson-Hodel, A. R.; Berg, A. L.; Wald, J. H.; Hatakeyama, J.; VanderVorst, K.; Curiel, 
D. A.; Leon, L. J.; Sweeney, C.; Carraway, K. L., Hexamethylene amiloride engages a novel 
reactive oxygen species- and lysosome-dependent programmed necrotic mechanism to 
selectively target breast cancer cells. Can. Lett. 2016, 375 (1), 62-72. 
48. Kleyman, T. R.; Cragoe, E. J., Jr., Cation transport probes: the amiloride series. Methods 
Enzymol. 1990, 191, 739-755. 
49. Cragoe, E. J.; Woltersdorf, O. W.; Bicking, J. B.; Kwong, S. F.; Jones, J. H., Pyrazine 
Diuretics. II. N-Amidino-3-amino-5-substituted 6-Halopyrazinecarboxamides. J. Med. Chem. 
1967, 10 (1), 66-75. 
50. Patwardhan, N. N.; Ganser, L. R.; Kapral, G. J.; Eubanks, C. S.; Lee, J.; Sathyamoorthy, 
B.; Al-Hashimi, H. M.; Hargrove, A. E., Amiloride as a new RNA-binding scaffold with activity 
against HIV-1 TAR. Med. Chem. Comm. 2017, 8 (5), 1022-1036. 
51. Zeslawska, E.; Schweinitz, A.; Karcher, A.; Sondermann, P.; Sperl, S.; Sturzebecher, J.; 
Jacob, U., Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex 
with small molecule inhibitors open the way towards structure-based drug design. J. Mol. Biol. 
2000, 301 (2), 465-475. 
52. Lee, S.; Yi, K. Y.; Hwang, S. K.; Lee, B. H.; Yoo, S.-e.; Lee, K., (5-Arylfuran-2-
ylcarbonyl)guanidines as cardioprotectives through the inhibition of Na+/H+ exchanger isoform-
1. J. Med. Chem. 2005, 48 (8), 2882-2891. 
53. Cochran, B. J.; Gunawardhana, L. P.; Vine, K. L.; Lee, J. A.; Lobov, S.; Ranson, M., The 
CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell 
surface uPA activity. BMC Biotechnol. 2009, 9, 43, 1-9. 
54. Yung-Chi, C.; Prusoff, W. H., Relationship between the inhibition constant (KI) and the 
concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. 
Biochem. Pharmacol. 1973, 22 (23), 3099-3108. 
55. Nienaber, V.; Wang, J.; Davidson, D.; Henkin, J., Re-engineering of human urokinase 
provides a system for structure-based drug design at high resolution and reveals a novel 
structural subsite. J. Biol. Chem. 2000, 275 (10), 7239-7248. 
56. Bachovchin, D. A.; Koblan, L. W.; Wu, W.; Liu, Y.; Li, Y.; Zhao, P.; Woznica, I.; Shu, 
Y.; Lai, J. H.; Poplawski, S. E.; Kiritsy, C. P.; Healey, S. E.; DiMare, M.; Sanford, D. G.; 
Munford, R. S.; Bachovchin, W. W.; Golub, T. R., A high-throughput, multiplexed assay for 
superfamily-wide profiling of enzyme activity. Nat. Chem. Biol. 2014, 10 (8), 656-663. 
57. Soisson, S. M.; Patel, S. B.; Abeywickrema, P. D.; Byrne, N. J.; Diehl, R. E.; Hall, D. L.; 
Ford, R. E.; Reid, J. C.; Rickert, K. W.; Shipman, J. M.; Sharma, S.; Lumb, K. J., Structural 
 78
definition and substrate specificity of the S28 protease family: the crystal structure of human 
prolylcarboxypeptidase. BMC. Struct. Biol. 2010, 10, 16, 1-8. 
58. Soudijn, W.; Van Wijngaarden, I.; AP, I. J., Allosteric modulation of G protein-coupled 
receptors: perspectives and recent developments. Drug. Discov. Today. 2004, 9 (17), 752-758. 
59. Gao, Z. G.; Ijzerman, A. P., Allosteric modulation of A(2A) adenosine receptors by 
amiloride analogues and sodium ions. Biochem. Pharmacol. 2000, 60 (5), 669-676. 
60. Garritsen, A.; Beukers, M. W.; Ijzerman, A. P.; Soudijn, W., Recognition of adenosine 
receptors by amiloride and its analogues. Nucleosides Nucleotides 1991, 10 (5), 1107-1111. 
61. Garritsen, A.; Ijzerman, A. P.; Tulp, M. T.; Cragoe, E. J., Jr.; Soudijn, W., Receptor 
binding profiles of amiloride analogues provide no evidence for a link between receptors and the 
Na+/H+ exchanger, but indicate a common structure on receptor proteins. J. Recept. Res. 1991, 
11 (6), 891-907. 
62. de Lera Ruiz, M.; Lim, Y.-H.; Zheng, J., Adenosine A2A receptor as a drug discovery 
target. J. Med. Chem. 2014, 57 (9), 3623-3650. 
63. Massink, A.; Louvel, J.; Adlere, I.; van Veen, C.; Huisman, B. J.; Dijksteel, G. S.; Guo, 
D.; Lenselink, E. B.; Buckley, B. J.; Matthews, H.; Ranson, M.; Kelso, M.; AP, I. J., 5'-
Substituted amiloride derivatives as allosteric modulators binding in the sodium ion pocket of the 
adenosine A2A receptor. J. Med. Chem. 2016, 59 (10), 4769-4777. 
64. Klinghofer, V.; Stewart, K.; McGonigal, T.; Smith, R.; Sarthy, A.; Nienaber, V.; Butler, 
C.; Dorwin, S.; Richardson, P.; Weitzberg, M.; Wendt, M.; Rockway, T.; Zhao, X.; Hulkower, 
K. I.; Giranda, V. L., Species specificity of amidine-based urokinase inhibitors. Biochemistry 
2001, 40 (31), 9125-9131. 
65. McNay, J. L.; Oran, E., Possible predisposition of diabetic patients to hyperkalemia 
following administration of potassium-retaining diuretic, amiloride (MK 870). Metabolism 1970, 
19 (1), 58-70. 
66. Baer, J. E.; Jones, C. B.; Spitzer, S. A.; Russo, H. F., The potassium-sparing and 
natriuretic activity of N-amidino-3,5-diamino-6-chloropyrazinecarboxamide hydrochloride 
dihydrate (amiloride hydrochloride). J. Pharmacol. Exp. Ther. 1967, 157 (2), 472-485. 
67. Comprehensive pharmacokinetic profiling of compounds 18 and 26 will be reported 
elsewhere. 
68. Uhland, K.; Siphos, B.; Arkona, C.; Schuster, M.; Petri, B.; Steinmetzer, P.; Mueller, F.; 
Schweinitz, A.; Steinmetzer, T.; Van De Locht, A., Use of IHC and newly designed matriptase 
inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma. Int. J. Oncol. 
2009, 35 (2), 347-357. 
69. Pothula, S. P.; Xu, Z.; Goldstein, D.; Biankin, A. V.; Pirola, R. C.; Wilson, J. S.; Apte, 
M. V., Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer. 
Br. J. Cancer. 2016, 114 (3), 269-280. 
70. Nikishkin, N. I.; Huskens, J.; Verboom, W., Transition metal-catalyzed functionalization 
of pyrazines. Org. Biomol. Chem. 2013, 11 (22), 3583-3602. 
71. Chessell, I. P.; Michel, A. D.; Humphrey, P. P., Properties of the pore-forming P2X7 
purinoceptor in mouse NTW8 microglial cells. Br. J. Pharmacol. 1997, 121 (7), 1429-1437. 
72. Amith, S. R.; Wilkinson, J. M.; Fliegel, L., KR-33028, a potent inhibitor of the 
Na(+)/H(+) exchanger NHE1, suppresses metastatic potential of triple-negative breast cancer 
cells. Biochem. Pharmacol. 2016, 118, 31-39. 
73. Rosenberg, M. R.; Weaver, L. M.; Casarotto, M. G., Probing interactions of Vpu from 
HIV-1 with amiloride-based compounds. Biochim. Biophys. Acta. 2016, 1858 (4), 733-739. 
 79
74. Jalily, P. H.; Eldstrom, J.; Miller, S. C.; Kwan, D. C.; Tai, S. S.-H.; Chou, D.; Niikura, 
M.; Tietjen, I.; Fedida, D., Mechanisms of action of novel influenza A/M2 viroporin inhibitors 
derived from hexamethylene amiloride. Mol. Pharmacol. 2016, 90 (2), 80-95. 
75. Heitman, L. H.; Ye, K.; Oosterom, J.; Ijzerman, A. P., Amiloride derivatives and a 
nonpeptidic antagonist bind at two distinct allosteric sites in the human gonadotropin-releasing 
hormone receptor. Mol. Pharmacol. 2008, 73 (6), 1808-1815. 
76. Snell, H. D.; Gonzales, E. B., 5-(N, N-Hexamethylene) amiloride is a GABA-A ρ1 
receptor positive allosteric modulator. Channels 2016, 10 (6), 498-506. 
77. Leng, T. D.; Si, H. F.; Li, J.; Yang, T.; Zhu, M.; Wang, B.; Simon, R. P.; Xiong, Z. G., 
Amiloride analogs as ASIC1a inhibitors. CNS. Neurosci. Ther. 2016, 22 (6), 468-476. 
78. Cox, G.; Ewart, G.; Gage, P., A Method of Modulating Ion Channel Functional Activity. 
PCT Int. Appl. WO2000021538 A1, Ed. 2000. 
79. Zhao, G.; Yuan, C.; Wind, T.; Huang, Z.; Andreasen, P. A.; Huang, M., Structural basis 
of specificity of a peptidyl urokinase inhibitor, upain-1. J. Struct. Biol. 2007, 160 (1), 1-10. 
80. Otwinowski, Z.; Minor, W., Processing of X-ray diffraction data collected in oscillation 
mode. Methods. Enzymol. 1997, 276, 307-326. 
81. CCP4, The CCP4 suite; Programs for protein crystallography. Acta. Cryst. 1994, D50, 
760-763. 
82. Jiang, L.; Botkjaer, K. A.; Andersen, L. M.; Yuan, C.; Andreasen, P. A.; Huang, M., 
Rezymogenation of active urokinase induced by an inhibitory antibody. Biochem. J. 2013, 449 
(1), 161-166. 
83. Emsley, P.; Cowtan, K., Coot: model-building tools for molecular graphics. Acta. 
Crystallogr. D Biol. Crystallogr. 2004, 60 (Pt 12 Pt 1), 2126-2132. 
84. Lu, M.; Echeverri, F.; Kalabat, D.; Laita, B.; Dahan, D. S.; Smith, R. D.; Xu, H.; 
Staszewski, L.; Yamamoto, J.; Ling, J.; Hwang, N.; Kimmich, R.; Li, P.; Patron, E.; Keung, W.; 
Patron, A.; Moyer, B. D., Small molecule activator of the human epithelial sodium channel. J. 
Biol. Chem. 2008, 283 (18), 11981-11994. 
85. Xu, Z.; Vonlaufen, A.; Phillips, P. A.; Fiala-Beer, E.; Zhang, X.; Yang, L.; Biankin, A. 
V.; Goldstein, D.; Pirola, R. C.; Wilson, J. S.; Apte, M. V., Role of pancreatic stellate cells in 
pancreatic cancer metastasis. Am. J. Pathol. 2010, 177 (5), 2585-2596. 
 
 
 
 
